Condensed azines for EP300 or CBP modulation and indications therefor

Abstract

Disclosed are compounds of Formula I or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics>, <semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Description

CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application Serial No. 62 / 831,622, filed on April 9, 2019. FIELD

[0002] The present invention relates to organic compounds useful for therapy in mammals, and in particular for modulating EP300 or CBP for various diseases associated with the overexpression of EP300 or CBP. BACKGROUND

[0003] Adenovirus E1A-associated 300 kDa protein (EP300, also referred to as P300 or KAT3B) and CREB-binding protein (CBP, also referred to as CREBBP or KAT3A) have homologous bromodomain- containing transcription coactivation factors, assembling with other proteins to cause the initiation of expression of specific genes. More specifically, EP300 and CBP are histone acetyltransferases (HATs) that acetylate both histone and non-histone proteins that play a role in gene expression regulation, transcription, and cell cycle regulation. The acetylation status of lysine residues in histone tails is one of a number of epigenetic post-translational modifications that alter DNA-templated processes, such as transcription, to facilitate malignant transformation. Protein acetylation also helps to block poly- ubiquitinylation, thereby preventing proteosomal degradation and cell death. (Giotopoulos et al. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia, Oncogene, 2016 January 21; 35(3): 279–289.) Bromodomains, including BDR4, are the readers of the acetyl marks in histone tails that are written by EP300 / CBP, and thus, bromodomains, EP300, and CBP all share the same pathway in the regulation of gene transcription (Perez-Salvia et al., Bromodomain inhibitors and cancer therapy: From structures to applications, Epigenetics & Chromatin, 2018, 11:30). These proteins interact with many others involved in transcription and cell cycle regulation, and products of oncogenes and fused genes (Giotopoulos et al., 2016).

[0004] It has been found that inhibition of CBP or EP300 has an inhibitory effect on the growth of acute myeloid leukemia cells, and EP300 and CPB are promising therapeutic targets across multiple subtypes of acute myeloid leukemia (AML) (Giotopoulos et al., 2016). It has further been reported that inactivating mutations of acetyltransferase genes in B-cell lymphoma. (Mullighan et al., CREBBP mutations in relapsed acute lymphoblastic leukemia, Nature, 2011; 471(7337): 235-9.)

[0005] It has also been reported that CPB or EP300 inhibition abrogates the viability of multiple myeloma cell lines as a result of direct transcriptional suppression of the lymphocyte-specific transcription factor IRF4, which is necessary for the viability of myeloma cells, and that CBP / EP300 inhibition is a viable therapeutic strategy for targeting multiple myeloma and other lymphoid malignancies dependent on the IRF4 network (Conery et al, Bromodomain inhibition of the transcriptional coactivators CBP / EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. https: / / doi.org / 10.7554 / eLife.10483.001).

[0006] EP300 inhibition can also stimulate autophagy to produce antiaging effect. For example, Spermidine is a polyamine agent that that delays age-related disease and death by acting as an EP300 inhibitor that stimulates autophagy to produce an anti-aging effect (Madeo et al., Spermidine delays ageing in humans, Aging, 2018, Vol. 10, No. 8).

[0007] It has also been shown that inhibition of CBP or EP300 can downregulate the expression of AR (androgen receptor) dependent cancer cells, and this has been demonstrated in AR-dependent prostate cancer cells lines and AR-dependent breast cancer tumors (Garcia-Carpizo et al., CREBBP / EP300 bromodomain inhibitors in breast cancer, Mol. Cancer Res., 17(3) March 2019).

[0008] Compounds that can inhibit EP300 or CBP, therefore, represent a new class of potential therapeutics capable of modulating histone acetyltransferases (HATs) which acetylate histone and non- histone proteins. As there are no EP300 or CBBP inhibitors that are currently approved for the treatment or prevention of diseases in humans, there is an unmet need for new compounds that are capable of modulating EP300 or CBP. SUMMARY

[0009] One embodiment of the disclosure relates to novel compounds, as described in any of the embodiments herein, or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein these novel compounds can modulate EP300 or CBP.

[0010] Another embodiment of this disclosure relates to a compound of Formula I: [Image disponible dans le document PDF, Image available in the PDF document] - - wherein <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics>, <semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>, or <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> are as described in any of the embodiments described in this disclosure.

[0011] Other embodiments and sub-embodiments of Formula I are further described herein in this disclosure.

[0012] Another embodiment of the disclosure relates to a pharmaceutical composition comprising a compound according to Formula I or any embodiment and sub-embodiment of Formula I described herein in this disclosure, or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog of any of these compounds, and a pharmaceutically acceptable carrier or excipient.

[0013] Another embodiment of the disclosure relates to a pharmaceutical composition comprising a compound according to Formula I, or any embodiment of Formula I described herein in this disclosure, or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog of any of these compounds, and another therapeutic agent.

[0014] Another embodiment of this disclosure relates to a method for treating a subject with a disease or condition mediated by EP300 or CBP, said method comprising administering to the subject an effective amount of a compound according to Formula I, or any embodiment of Formula I described in this disclosure, or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog of any of these compounds, or a pharmaceutical composition of any of the compounds as described in this disclosure, wherein the disease or condition comprises expression, aberrantly or otherwise, of EP300 or CBP, or activating mutations or translocations of any of the foregoing.

[0015] Additional embodiments are described are further described in the Detailed Description of this disclosure. DETAILED DESCRIPTION I. Definitions

[0016] As used herein the following definitions apply unless clearly indicated otherwise:

[0017] It is noted here that as used herein and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

[0018] Unless a point of attachment indicates otherwise, the chemical moieties listed in the definitions of the variables of Formula I of this disclosure, and all the embodiments thereof, are to be read from left to right, wherein the right hand side is directly attached to the parent structure as defined. However, if a point of attachment (e.g., a dash "-") is shown on the left hand side of the chemical moiety (e.g., - alkyloxy-(C1-C25)alkyl), then the left hand side of this chemical moiety is attached directly to the parent moiety as defined.

[0019] It is assumed that when considering generic descriptions of compounds described herein for the purpose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that, theoretically, some constructs would not normally be considered as stable compounds (that is, sterically practical and / or synthetically feasible).

[0020] "Alkyl," by itself, or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon, having the number of carbon atoms designated (i.e. C1-6 means one to six carbons). Representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. Further representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. For each of the definitions herein (e.g., alkyl, alkoxy, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, etc.), when a prefix is not included to indicate the number of carbon atoms in an alkyl portion, the alkyl moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms or 6 or fewer main chain carbon atoms. For example, <semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics> alkyl refers to a straight or branched hydrocarbon having 1, 2, 3, 4, 5 or 6 carbon atoms and includes, but is not limited to, -CH3, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C1-2 alkyl, C2 alkyl, C3 alkyl, C1-3 alkyl, C1-4 alkyl, C1-5 alkyl, C1-6 alkyl, C2-3 alkyl, C2-4 alkyl, C2-5 alkyl, C2-6 alkyl, C3-4 alkyl, C3-5 alkyl, C3-6 alkyl, C4-5 alkyl, C4-6 alkyl, C5-6 alkyl and C6 alkyl. While it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as -OR (e.g. alkoxy), -SR (e.g. thioalkyl), -NHR (e.g. alkylamino), -C(O)NHR, and the like, substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any O, S, or N of the moiety (except where N is a heteroaryl ring atom) excludes substituents that would result in any O, S, or N of the substituent (except where N is a heteroaryl ring atom) being bound to the alkyl carbon bound to any O, S, or N of the moiety.

[0021] "Alkylene" by itself or as part of another substituent means a linear or branched saturated divalent hydrocarbon moiety derived from an alkane having the number of carbon atoms indicated in the prefix. For example, (i.e., <semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics> means one to six carbons; <semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics> alkylene is meant to include methylene, ethylene, propylene, 2-methylpropylene, pentylene, hexylene and the like). <semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics> alkylene includes methylene -CH2-, ethylene -CH2CH2-, propylene -CH2CH2-, and isopropylene -CH(CH3)CH2-, -CH2CH(CH3)-, -CH2-(CH2)2CH2-, -CH2-CH(CH3)CH2-, -CH2-C(CH3)2-CH2-CH2CH(CH3)-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer, 8 or fewer, or 6 or fewer carbon atoms. When a prefix is not included to indicate the number of carbon atoms in an alkylene portion, the alkylene moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms, 6 or fewer main chain carbon atoms, or 4 or fewer main chain carbon atoms, or 3 or fewer main chain carbon atoms, or 2 or fewer main chain carbon atoms, or 1 c irbon atom.

[0022] "Alkenyl" refers to a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical having the number of carbon atoms indicated in the prefix and containing at least one double bond. For example, C2-C6 alkenyl is meant to include ethenyl, propenyl, and the like. "C2- C6alkenylC1-C6alkylene" is a group -C1-C6alkylene-C2-C6alkenyl, where alkenyl and alkylene are as defined herein.

[0023] The term "alkenylene" refers to a linear divalent hydrocarbon radical or a branched divalent hydrocarbon radical containing at least one double bond and having the number of carbon atoms indicated in the prefix.

[0024] The term "alkynyl" refers to a monoradical of an unsaturated hydrocarbon, in some embodiments, having from 2 to 20 carbon atoms (in some embodiments, from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon triple bonds e.g. 1, 2 or 3 carbon-carbon triple bonds. In some embodiments, alkynyl groups include ethynyl (-C=CH), propargyl (or propynyl, e.g. -C≡CCH3), and the like. When a prefix is not included to indicate the number of carbon atoms in an alkenyl or alkynyl portion, the alkenyl or alkynyl moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms, 6 or fewer main chain carbon atoms or 4 or fewer main chain carbon atoms.

[0025] The term "alkynylene" refers to a linear divalent hydrocarbon radical or a branched divalent hydrocarbon radical containing at least one triple bond and having the number of carbon atoms indicated in the prefix. Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.

[0026] "Alkoxy" or "alkoxyl" refers to a –O-alkyl group, where alkyl is as defined herein. By way of example, "C1-C6alkoxy" refers to a –O-C1-C6alkyl group, where alkyl is as defined herein. While it is understood that substitutions on alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that O, S, or N (except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy O. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an O, S, or N of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety.

[0027] The terms "alkoxyalkyl" and "alkoxyalkylene" refer to an alkyl group substituted with an alkoxy group. By way of example, "<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkoxy<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl" refers to <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl substituted with a <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- <semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkoxy where alkyl and alkoxy are as defined herein, while "<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkoxy<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkylene" refers to <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkyl substituted with a <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkoxy where alkylene and alkoxy are as defined herein.

[0028] "Alkylsulfonyl" refers to a group -S(O)2-alkyl, for example, C1-C6alkylsulfonyl is a group - <semantics>S(O)2<annotation encoding="application / x-tex">S(O)_2< / annotation>< / semantics>-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl. "Alkylsulfonylalkylene" refers to a group alkylene-<semantics>S(O)2<annotation encoding="application / x-tex">S(O)_2< / annotation>< / semantics>-alkyl, for example, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- <semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylsulfonyl<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylene is -<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylene-<semantics>S(O)2<annotation encoding="application / x-tex">S(O)_2< / annotation>< / semantics>-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl.

[0029] "Amino" or "amine" denotes the group -NH2.

[0030] "Alkylamino" refers to a –NH-alkyl group, where alkyl is as defined herein. Exemplary alkylamino groups include CH3NH-, ethylamino, and the like. By way of example, C1-C6alkylamino refers to <semantics>−N(H)C1−C6<annotation encoding="application / x-tex">-N(H)C_1-C_6< / annotation>< / semantics>alkyl.

[0031] The terms "aminoalkyl" and "aminoalkylene" refer to -alkylene-NH2. By way of example, C1- C6aminoalkyl refers to -C1-C6alkyl-NH2. "Alkylaminoalkylene" refers to an -alkylene-NH-alkyl group, for example, C1-C6alkylaminoC1-C6alkylene is a group -C1-C6alkylene-NH-C1-C6alkyl.

[0032] "Dialkylamino" refers to a –N(alkyl)(alkyl) group, where each alkyl is independently as defined herein. Exemplary dialkylamino groups include dimethylamino, diethylamino, ethylmethylamino, and the like. Di-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylamino refers to -<semantics>N(C1<annotation encoding="application / x-tex">N(C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl)2.

[0033] "Cycloalkyl" or "Carbocycle" or "Carbocyclic" by itself, or as part of another substituent, unless otherwise stated, refers to saturated or partially unsaturated, non-aromatic monocyclic ring, or fused rings, such as bicyclic or tricyclic carbon ring systems, or cubane, having the number of carbon atoms indicated in the prefix or if unspecified having 3-6, also 4-6, and also 5-6 ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, where one or two ring carbon atoms may optionally be replaced by a carbonyl. Further, the term cycloalkyl is intended to encompass ring systems fused to an aromatic ring (e.g., of an aryl or heteroaryl), regardless of the point of attachment to the remainder of the molecule. Cycloalkyl refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C3-6) cycloalkyl and 3-6 membered cycloalkyl both mean three to six ring carbon atoms). The term "cycloalkenyl" refers to a cycloalkyl having at least one unit of unsaturation. A substituent of a cycloalkyl or cycloalkenyl may be at the point of attachment of the cycloalkyl or cycloalkenyl group, forming a quaternary center.

[0034] "Cycloalkylalkyl" and "cycloalkylalkylene" refer to an -(alkylene)-cycloalkyl group where alkylene as defined herein has the indicated number of carbon atoms or if unspecified having six or fewer carbon atoms; and cycloalkyl is as defined herein has the indicated number of carbon atoms or if unspecified having 3-10, also 3-8, and also 3-6, ring members per ring. By way of example, 4-6 membered cycloalkyl-C1-C6alkyl refers to a cycloalkyl with 4-6 carbon atoms attached to an alkylene chain with 1-6 carbon atoms, wherein the alkylene chain is attached to the parent moiety. Other exemplary cycloalkylalkyl includes, e.g., cyclopropylmethylene, cyclobutylethylene, cyclobutylmethylene, and the like. "Cycloalkylalkynylene" refers to a -(alkynylene)-cycloalkyl group, for example, C3-C6cycloalkylC2-C6alkynylene is a group -(C2-C6alkynylene)-C3-C6cycloalkyl. "C3- C6cycloalkylethynylene" is a group <semantics>−C≡C−C3−C6<annotation encoding="application / x-tex">-C \equiv C - C_3 - C_6< / annotation>< / semantics>cycloalkyl.

[0035] "Cycloalkylalkoxy" refers to an -(alkoxy)-cycloalkyl group where alkoxy as defined herein has the indicated number of carbon atoms, or if unspecified has six or fewer carbon atoms; and cycloalkyl is as defined herein and has the indicated number of carbon atoms, or if unspecified has 3-10, also 3-8, or 3-6, ring members per ring. By way of example, <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cycloalkylalkoxy refers to a cycloalkyl with 3-6 ring carbon atoms attached to an alkoxy having one to six carbon atoms, wherein the alkoxy chain is attached to the parent moiety. Other exemplary cycloalkylalkoxy include, e.g., cyclopropylmethoxy, cyclobutylethoxy, cyclobutylmethoxy, and the like.

[0036] The term "cyano" refers to the group -CN. The term "<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cyanoalkyl" refers to a <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, as defined herein, that is substituted with 1, 2 or 3 cyano groups. "C1-C6cyanoalkylethynylene" is a group <semantics>−C≡C−C1−C6cyanoalkyl<annotation encoding="application / x-tex">-C \equiv C - C_1 - C_6 cyanoalkyl< / annotation>< / semantics>.

[0037] "Aryl" by itself, or as part of another substituent, unless otherwise stated, refers to a monocyclic, bicyclic or polycyclic polyunsaturated aromatic hydrocarbon radical containing 6 to 14 ring carbon atoms, which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl rings are fused with a heteroaryl ring, the resulting ring system is heteroaryl. Non-limiting examples of unsubstituted aryl groups include phenyl, 1-naphthyl and 2-naphthyl. The term "arylene" refers to a divalent aryl, wherein the aryl is as defined herein.

[0038] "Arylalkyl" or "aralkyl" refers to -(alkylene)-aryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and aryl is as defined herein. Examples of arylalkyl include benzyl, phenethyl, 1-methylbenzyl, and the like. In another example, phenyl-C1-C6alkoxy refers to a phenyl group attached to <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkoxy group, wherein <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkoxy is as defined herein and is attached to the parent moiety.

[0039] The term "haloalkyl" refers to an alkyl substituted by one to seven halogen atoms. Haloalkyl includes monohaloalkyl or polyhaloalkyl. For example, the term "C1-C6haloalkyl" is meant to include trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Further, the term "haloalkylene" refers to an alkylene substituted by one to seven halogen atoms.

[0040] "Halogen" or "halo" refers to all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), or iodo (I).

[0041] The term "haloalkoxy" refers to an alkoxy substituted by one to seven halogen atoms. Haloalkoxy includes monohaloalkoxy or polyhaloalkoxy. For example, the term "C1-C6haloalkoxy" is meant to include trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, 4-chlorobutoxy, 3- bromopropoxy, and the like.

[0042] "Heteroatom" is meant to include oxygen (O), nitrogen (N), and sulfur (S).

[0043] "Heteroaryl" refers to a monocyclic or bicyclic aromatic ring radical containing 5-9 ring atoms (also referred to in this disclosure as a 5-9 membered heteroaryl), including monocyclic aromatic ring radicals containing 5 or 6 ring atoms (also referred to in this disclosure as a 5-6 membered heteroaryl), containing one or more, 1-4, 1-3, or 1-2, heteroatoms independently selected from the group consisting of O, S, and N. Any aromatic ring or ring system containing at least one heteroatom is a heteroaryl regardless of the point of attachment (i.e., through any one of the fused rings). Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrazinyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, indolyl, triazinyl, quinoxalinyl, cinnolinyl, phthalazinyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzothienyl, quinolyl, isoquinolyl, indazolyl, pteridinyl and thiadiazolyl. "Nitrogen containing heteroaryl" refers to heteroaryl wherein at least one of the ring heteroatoms is N.

[0044] "Heteroarylalkyl" refers to -(alkylene)-heteroaryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heteroaryl is as defined herein.

[0045] "Heterocycloalkyl" refers to a saturated or partially unsaturated non-aromatic cycloalkyl group that contains from one to five heteroatoms selected from N, O, S (including S(O) and S(O)2), or P (including phosphine oxide) wherein the nitrogen, sulfur, and phosphorous atoms are optionally oxidized, and the nitrogen atom(s) are optionally quarternized, the remaining ring atoms being C, where one or two C atoms may optionally be present as a carbonyl. Further, the term heterocycloalkyl is intended to encompass any ring or ring system containing at least one heteroatom that is not a heteroaryl, regardless of the point of attachment to the remainder of the molecule. Heterocycloalkyl groups include those having a ring with a formally charge-separated aromatic resonance structure, for example, N- methylpyridonyl. The heterocycloalkyl may be substituted with one or two oxo groups, and can include sulfone and sulfoxide derivatives. The heterocycloalkyl may be a monocyclic, a fused bicyclic or a fused polycyclic ring system of 3 to 12, 4 to 10, 5 to 10, or 5 to 6 ring atoms in which one to five ring atoms are heteroatoms selected from <semantics>−N=<annotation encoding="application / x-tex">-N=< / annotation>< / semantics>, <semantics>−N−<annotation encoding="application / x-tex">-N-< / annotation>< / semantics>, <semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>, <semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>, <semantics>−S(O)−<annotation encoding="application / x-tex">-S(O)-< / annotation>< / semantics>, or <semantics>−S(O)2−<annotation encoding="application / x-tex">-S(O)_2-< / annotation>< / semantics> and further wherein one or two ring atoms are optionally replaced by a -C(O)- group. As an example, a 4-6 membered heterocycloalkyl is a heterocycloalkyl with 4-6 ring members having at least one heteroatom. The heterocycloalkyl can also be a heterocyclic alkyl ring fused with a cycloalkyl. Non limiting examples of heterocycloalkyl groups include pyrrolidinyl, piperidinyl, morpholinyl, pyridonyl, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom. The "heterocycloalkenyl" refers to a heterocycloalkyl having at least one unit of unsaturation. A substituent of a heterocycloalkyl or heterocycloalkenyl may be at the point of attachment of the heterocycloalkyl or heterocycloalkenyl group, forming a quaternary center.

[0046] "Heterocycloalkylalkyl" or "heterocyclylalkyl" refers to -(alkylene)-heterocycloalkyl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heterocycloalkyl is as defined herein.

[0047] "Hydroxyl" or "hydroxy" refers to the group -OH. The term "hydroxyalkyl" or "hydroxyalkylene" refers to an alkyl group or alkylene group, respectively as defined herein, substituted with 1-5 hydroxy groups.

[0048] The term "<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics> haloalkoxy" refers to <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics> alkoxy as defined herein that is substituted with one or more halogen atoms.

[0049] The term "oxo" refers to <semantics>C(=0)<annotation encoding="application / x-tex">C(=0)< / annotation>< / semantics> or <semantics>(0)<annotation encoding="application / x-tex">(0)< / annotation>< / semantics>. In some embodiments, two possible points of attachment on a carbon form an oxo group.

[0050] "Optional substituents" or "optionally substituted" as used throughout the disclosure means that the substitution on a compound may or may not occur, and that the description includes instances where the substitution occurs and instances in which the substitution does not. For example, the phrase "optionally substituted with 1-4 <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> groups" means that the <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> group may but need not be present. It is assumed in this disclosure that optional substitution on a compound occurs in a way that would result in a stable compound.

[0051] As used herein in connection with compounds of the disclosure, the term "synthesizing" and like terms means chemical synthesis from one or more precursor materials.

[0052] As used herein, the term "composition" refers to a formulation suitable for administration to an intended animal subject for the rapeutic purposes that contains at least one pharmaceutically active compound and at least one pharmaceutically acceptable carrier or excipient.

[0053] The term "pharmaceutically acceptable" indicates that the indicated material does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. For example, it is commonly required that such a material be essentially sterile, e.g., for injectables.

[0054] "Pharmaceutically acceptable salt" refers to a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). Contemplated pharmaceutically acceptable salt forms include, without limitation, mono, bis, tris, tetrakis, and so on. Pharmaceutically acceptable salts are non-toxic in the amounts and concentrations at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of a compound without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug. Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically-acceptable inorganic or organic acids, depending on the particular substituents found on the compounds described herein.

[0055] Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free-base form of a compound can be dissolved in a suitable solvent, such as an aqueous or aqueous- alcohol solution containing the appropriate acid and then isolated by evaporating the solution. In another example, a salt can be prepared by reacting the free base and acid in an organic solvent.

[0056] When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base (i.e. a primary, secondary, tertiary, quaternary, or cyclic amine; an alkali metal hydroxide; alkaline earth metal hydroxide; or the like), either neat or in a suitable inert solvent. The desired acid can be, for example, a pyranosidyl acid (such as glucuronic acid or galacturonic acid), an alpha-hydroxy acid (such as citric acid or tartaric acid), an amino acid (such as aspartic acid or glutamic acid), an aromatic acid (such as benzoic acid or cinnamic acid), a sulfonic acid (such as p-toluenesulfonic acid or ethanesulfonic acid), or the like. In some embodiments, salts can be derived from pharmaceutically acceptable acids such as acetic, trifluoroacetic, propionic, ascorbic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, glycolic, gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, oxalic, methanesulfonic, mucic, naphthalenesulfonic, nicotinic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, sulfamic, hydroiodic, carbonic, tartaric, p-toluenesulfonic, pyruvic, aspartic, benzoic, cinnamic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, embonic (pamoic), ethanesulfonic, benzenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylsulfamic, cyclohexylaminosulfonic, quinic, algenic, hydroxybutyric, galactaric and galacturonic acid and the like.

[0057] Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M. et al, "Pharmaceutical Salts," J. Pharmaceutical Science, 1977, 66:1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0058] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

[0059] The pharmaceutically acceptable salt of the different compounds may be present as a complex. Examples of complexes include 8-chlorotheophylline complex (analogous to, e.g., dimenhydrinate: diphenhydramine 8-chlorotheophylline (1:1) complex; Dramamine) and various cyclodextrin inclusion complexes.

[0060] The term "deuterated" as used herein alone or as part of a group, means substituted deuterium atoms. The term "deuterated analog" as used herein alone or as part of a group, means substituted deuterium atoms in place of hydrogen. The deuterated analog of the disclosure may be a fully or partially deuterium substituted derivative. In some embodiments, the deuterium substituted derivative of the disclosure holds a fully or partially deuterium substituted alkyl, aryl or heteroaryl group.

[0061] The disclosure also embraces isotopically-labeled compounds of the present disclosure which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are intended to be encompassed within the scope of the present disclosure. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. Unless otherwise stated, when a position is designated specifically as "H" or "hydrogen," the position is understood to have hydrogen at its natural abundance isotopic composition or its isotopes, such as deuterium (D) or tritium (3H). Certain isotopically-labeled compounds of the present disclosure (e.g., those labeled with 3H and 14C) are useful in compound and / or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) and fluorine-18 (18F) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the present disclosure can generally be prepared by following procedures analogous to those described in the Schemes and in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0062] "Prodrugs" means any compound which releases an active parent drug according to Formula I in vivo when such prodrug is administered to a subject. Prodrugs of a compound of Formula I are prepared by modifying functional groups present in the compound of Formula I in such a way, either in routine manipulation or in vivo, that the modifications may be cleaved in vivo to release the parent compound. Prodrugs may proceed from prodrug form to active form in a single step or may have one or more intermediate forms which may themselves have activity or may be inactive. Some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound. Prodrugs include compounds of Formula I wherein a hydroxy, amino, carboxyl or sulfhydryl group in a compound of Formula I is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), amides, guanidines, carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds of Formula I, and the like. Other examples of prodrugs include, without limitation, carbonates, ureides, solvates, or hydrates of the active compound. Preparation, selection, and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series; "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

[0006] As described in The Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, CA, 2001), prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. Generally, bioprecursor prodrugs are compounds that are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity. Typically, the formation of active drug compound involves a metabolic process or reaction that is one of the follow types:

[0007] (1) Oxidative reactions: Oxidative reactions are exemplified without limitation to reactions such as oxidation of alcohol, carbonyl, and acid functionalities, hydroxylation of aliphatic carbons, hydroxylation of alicyclic carbon atoms, oxidation of aromatic carbon atoms, oxidation of carbon-carbon double bonds, oxidation of nitrogen-containing functional groups, oxidation of silicon, phosphorus, arsenic, and sulfur, oxidative N-dealkylation, oxidative O- and S-dealkylation, oxidative deamination, as well as other oxidative reactions.

[0008] (2) Reductive reactions: Reductive reactions are exemplified without limitation to reactions such as reduction of carbonyl functionalities, reduction of alcohol functionalities and carbon-carbon double bonds, reduction of nitrogen-containing functional groups, and other reduction reactions.

[0009] (3) Reactions without change in the oxidation state: Reactions without change in the state of oxidation are exemplified without limitation to reactions such as hydrolysis of esters and ethers, hydrolytic cleavage of carbon-nitrogen single bonds, hydrolytic cleavage of non-aromatic heterocycles, hydration and dehydration at multiple bonds, new atomic linkages resulting from dehydration reactions, hydrolytic dehalogenation, removal of hydrogen halide molecule, and other such reactions.

[0010] Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improves uptake and / or localized delivery to a site(s) of action. Desirably for such a carrier prodrug, the linkage between the drug moiety and the transport moiety is a covalent bond, the prodrug is inactive or less active than the drug compound, the prodrug and any release transport moiety are acceptably non-toxic. For prodrugs where the transport moiety is intended to enhance uptake, typically the release of the transport moiety should be rapid. In other cases, it is desirable to utilize a moiety that provides slow release, e.g., certain polymers or other moieties, such as cyclodextrins. (See, e.g., Cheng et al., U.S. Patent Publ. No. 2004 / 0077595.) Such carrier prodrugs are often advantageous for orally administered drugs. Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and / or improvement in drug formulation (e.g. stability, water solubility, suppression of an undesirable organoleptic or physiochemical property). For example, lipophilicity can be increased by esterification of hydroxyl groups with lipophilic carboxylic acids, or of carboxylic acid groups with alcohols, e.g., aliphatic alcohols.

[0011] The term "carrier" is also meant to include microspheres, liposomes, micelles, nanoparticles (naturally-equipped nanocarriers, for example, exosomes), and the like. It is known that exosomes can be highly effective drug carriers, and there are various ways in which drugs can be loaded into exosomes, including those techniques described in J Control Release. 2015 December 10; 219: 396–405.

[0012] Metabolites, e.g., active metabolites, overlap with prodrugs as described above, e.g., bioprecursor prodrugs. Thus, such metabolites are pharmacologically active compounds or compounds that further metabolize to pharmacologically active compounds that are derivatives resulting from metabolic process in the body of a subject. Of these, active metabolites are such pharmacologically active derivative compounds. For prodrugs, the prodrug compound is generally inactive or of lower activity than the metabolic product. For active metabolites, the parent compound may be either an active compound or may be an inactive prodrug.

[0013] Prodrugs and active metabolites may be identified using routine techniques known in the art. See, e.g., Bertolini et al., 1997, J. Med. Chem., 40:2011-2016; Shan et al., 1997, J Pharm Sci 86(7):756- 757; Bagshawe, 1995, Drug Dev. Res., 34:220-230.

[0014] "Tautomer" means compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See, Jerry March, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, Fourth Edition, John Wiley & Sons, pages 69-74 (1992). The tautomers also refer to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. Examples of include keto-enol tautomers, such as acetone / propen-2-ol, imine-enamine tautomers and the like, ring-chain tautomers, such as glucose / 2,3,4,5,6-pentahydroxy-hexanal and the like, the tautomeric forms of heteroaryl groups containing a -N=C(H)-NH- ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') can occur. The compounds described herein may have one or more tautomers and therefore include various isomers. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible. All such isomeric forms of these compounds are expressly included in the present disclosure.

[0072] "Isomers" mean compounds having identical molecular Formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers." "Stereoisomer" and "stereoisomers" refer to compounds that exist in different stereoisomeric forms, for example, if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Stereoisomers include enantiomers and diastereomers. Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers." When a compound has an asymmetric center, for example, an atom such as carbon bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture." As another example, stereoisomers include geometric isomers, such as cis- or trans- orientation of substituents on adjacent carbons of a double bond. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of ADVANCED ORGANIC CHEMISTRY, 6th edition J. March, John Wiley and Sons, New York, 2007) differ in the chirality of one or more stereocenters.

[0073] "Hydrate" refers to a complex formed by combination of water molecules with molecules or ions of the solute. "Solvate" refers to a complex formed by combination of solvent molecules with molecules or ions of the solute. The solvent can be an organic compound, an inorganic compound, or a mixture of both. Solvate is meant to include hydrate. Some examples of solvents include, but are not limited to, methanol, N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure.

[0074] In the context of the use, testing, or screening of compounds that are or may be modulators, the term "contacting" means that the compound(s) are caused to be in sufficient proximity to a particular molecule, complex, cell, tissue, organism, or other specified material that potential binding interactions and / or chemical reaction between the compound and other specified material can occur.

[0075] By "assaying" is meant the creation of experimental conditions and the gathering of data regarding a particular result of the exposure to specific experimental conditions. For example, enzymes can be assayed based on their ability to act upon a detectable substrate. A compound can be assayed based on its ability to bind to a particular target molecule or molecules.

[0076] As used herein, the terms "ligand" and "modulator" are used equivalently to refer to a compound that changes (i.e., increases or decreases) the activity of a target biomolecule, e.g., an enzyme such as those described herein. Generally a ligand or modulator will be a small molecule, where "small molecule refers to a compound with a molecular weight of 1500 Daltons or less, 1000 Daltons or less, 800 Daltons or less, or 600 Daltons or less. Thus, an "improved ligand" is one that possesses better pharmacological and / or pharmacokinetic properties than a reference compound, where "better" can be defined by one skilled in the relevant art for a particular biological system or therapeutic use.

[0077] The term "binds" in connection with the interaction between a target and a potential binding compound indicates that the potential binding compound associates with the target to a statistically significant degree as compared to association with proteins generally (i.e., non-specific binding). Thus, the term "binding compound" refers to a compound that has a statistically significant association with a target molecule. In some embodiments, a binding compound interacts with a specified target with a dissociation constant (KD) of 10 mM or less, 1,000 μM or less, 100 μM or less, 10 μM or less, 1 μM or less, 1,000 nM or less, 100 nM or less, 10 nM or less, or 1 nM or less. In the context of compounds binding to a target, the terms "greater affinity" and "selective" indicates that the compound binds more tightly than a reference compound, or than the same compound in a reference condition, i.e., with a lower dissociation constant. In some embodiments, the greater affinity is at least 2, 3, 4, 5, 8, 10, 50, 100, 200, 400, 500, 1000, or 10,000-fold greater affinity.

[0078] The terms "modulate," "modulation," and the like refer to the ability of a compound to increase or decrease the function and / or expression of a target, such as EP300 or CBP, where such function may include transcription regulatory activity and / or binding. Modulation may occur in vitro or in vivo. Modulation, as described herein, includes the inhibition, antagonism, partial antagonism, activation, agonism or partial agonism of a function or characteristic associated with EP300 or CBP, either directly or indirectly, and / or the upregulation or downregulation of the expression EP300 or CBP, either directly or indirectly. In another embodiment, the modulation is direct. Inhibitors or antagonists are compounds that, <semantics>ϵ<annotation encoding="application / x-tex">\epsilon< / annotation>< / semantics>.g., bind to, partially or totally block stimulation, decrease, prevent, inhibit, delay activation, inactivate, desensitize, or downregulate signal transduction. Activators or agonists are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, activate, sensitize or upregulate signal transduction.

[0079] As used herein, the terms "treat," "treating," "therapy," "therapies," and like terms refer to the administration of material, e.g., any one or more compound(s) as described herein in an amount effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or condition, i.e., indication, and / or to prolong the survival of the subject being treated.

[0080] The terms "prevent," "preventing," "prevention" and grammatical variations thereof as used herein, refers to a method of partially or completely delaying or precluding the onset or recurrence of a disease, disorder or condition and / or one or more of its attendant symptoms or barring a subject from acquiring or reacquiring a disorder or condition or reducing a subject's risk of acquiring or requiring a disorder or condition or one or more of its attendant symptoms.

[0081] As used herein, the term "subject," "animal subject," and the like refers to a living organism including, but not limited to, human and non-human vertebrates, e.g. any mammal, such as a human, other primates, sports animals and animals of commercial interest such as cattle, horses, ovines, or porcines, rodents, or pets such as dogs and cats.

[0082] "Unit dosage form" refers to a composition intended for a single administration to treat a subject suffering from a disease or medical condition. Each unit dosage form typically comprises each of the active ingredients of this disclosure plus pharmaceutically acceptable excipients. Examples of unit dosage forms are individual tablets, individual capsules, bulk powders, liquid solutions, ointments, creams, eye drops, suppositories, emulsions or suspensions. Treatment of the disease or condition may require periodic administration of unit dosage forms, for example: one unit dosage form two or more times a day, one with each meal, one every four hours or other interval, or only one per day. The expression "oral unit dosage form" indicates a unit dosage form designed to be taken orally.

[0083] The term "administering" refers to oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.

[0084] In the present context, the term "therapeutically effective" or "effective amount" indicates that a compound or material or amount of the compound or material when administered is sufficient or effective to prevent, alleviate, or ameliorate one or more symptoms of a disease, disorder or medical condition being treated, and / or to prolong the survival of the subject being treated. The therapeutically effect ve amount will vary depending on the compound, the disease, disorder or condition and its severity and the age, weight, etc., of the mammal to be treated. In general, satisfactory results in subjects are indicated to be obtained at a daily dosage of from about 0.1 to about 10 g / kg subject body weight. In some embodiments, a daily dose ranges from about 0.10 to 10.0 mg / kg of body weight, from about 1.0 to 3.0 mg / kg of body weight, from about 3 to 10 mg / kg of body weight, from about 3 to 150 mg / kg of body weight, from about 3 to 100 mg / kg of body weight, from about 10 to 100 mg / kg of body weight, from about 10 to 150 mg / kg of body weight, or from about 150 to 1000 mg / kg of body weight. The dosage can be conveniently administered, e.g., in divided doses up to four times a day or in sustained-release form.

[0085] The ability of a compound to inhibit the function of EP300 or CBP can be demonstrated in a biochemical assay, e.g., binding assay, or a cell-based assay.

[0086] As used herein, the term "EP300 or CBP mediated disease or condition" refers to a disease or condition in which the biological function of EP300, CBP, or both EP300 and CBP affect the development and / or course of the disease or condition, and / or in which modulation of EP300, CBP, or both EP300 and CBP alters the development, course, and / or symptoms. An EP300 or CBP mediated disease or condition includes a disease or condition for which EP300 inhibition, CBP inhibition, or both EP300 and CBP inhibition provides a therapeutic benefit, e.g. wherein treatment with EP300 or CBP inhibitors, including compounds described herein, provides a therapeutic benefit to the subject suffering from or at risk of the disease or condition. An EP300 or CBP mediated disease or condition is intended to include a cancer that harbors loss of function mutations in CBP or EP300, or a cancer where there is activation of EP300 or CBP. An EP300 or CBP mediated disease or condition is also intended to include a cancer that expresses the androgen receptor.

[0087] The term "EP300 mediated disease or disorder" includes a disease associated with or that implicates EP300 activity, for example, the overactivity of EP300, and conditions that accompany these diseases. The term "overactivity of EP300" refers to either: 1) EP300 expression in cells which normally do not express EP300; 2) increased EP300 expression leading to unwanted cell proliferation; or 3) mutations leading to constitutive activation of EP300. An EP300 mediated disease or disorder would include tumors with a CBP inactivating mutation, also known as synthetic lethality. Examples of an EP300 mediated diseases or disorders include a disorder resulting from abnormally high amount of EP300 activity. An EP300 mediated disease or condition is intended to include a cancer that harbors loss of a function mutation in CBP, or a cancer where there is activation of EP300. An EP300 mediated disease or condition is also intended to include a cancer that expresses the androgen receptor. It is known that overactivity of EP300 has been implicated in the pathogenesis of a number of diseases, including proliferative and non-proliferative disorders, including neoplastic disorders and cancers, inflammatory disorders, cognitive disorders and neurodegenerative diseases.

[0088] The term "CBP mediated disease or disorder" includes a disease associated with or that implicates CBP activity, for example, the overactivity of CBP, and conditions that accompany with these diseases. The term "overactivity of CBP" refers to either: 1) CBP expression in cells which normally do not express CBP; 2) increased CBP expression leading to unwanted cell proliferation; or 3) mutations leading to constitutive activation of CBP. Examples of CBP mediated diseases or disorders include a disorder resulting from abnormally high amount of CBP activity. A CBP mediated disease or condition is intended to include a cancer that harbors loss of a function mutation in EP300, or a cancer where there is activation of CBP. A CBP mediated disease or condition is also intended to include a cancer that expresses the androgen receptor. It is known that overactivity of CBP has been implicated in the pathogenesis of a number of diseases, including proliferative and non-proliferative disorders, including neoplastic disorders and cancers, inflammatory disorders, cognitive disorders and neurodegenerative diseases.

[0089] Also in the context of compounds binding to a biomolecular target, the term "greater specificity" indicates that a compound binds to a specified target to a greater extent than to another biomolecule or biomolecules that may be present under relevant binding conditions, where binding to such other biomolecules produces a different biological activity than binding to the specified target. Typically, the specificity is with reference to a limited set of other biomolecules, e.g., in the case of EP300, CBP or even other epigenetic targets. In particular embodiments, the greater specificity is at least 2, 3, 4, 5, 8, 10, 50, 100, 200, 400, 500, or 1000-fold greater specificity.

[0090] As used herein in connection with binding compounds or ligands, the term "specific for EP300," and terms of like import mean that a particular compound binds to EP300 to a statistically greater extent than to other epigenetic targets that may be present in a particular sample. Also, where biological activity other than binding is indicated, the term "specific for EP300" indicates that a particular compound has greater biological effect associated with binding EP300 than to other enzymes, e.g., enzyme activity inhibition. The specificity is also with respect to other biomolecules (not limited to EP300) that may be present in a particular sample.

[0091] As used herein in connection with binding compounds or ligands, the term "specific for CBP," and terms of like import mean that a particular compound binds to CBP to a statistically greater extent than to other epigenetic targets that may be present in a particular sample. Also, where biological activity other than binding is indicated, the term "specific for CBP" indicates that a particular compound has greater biological effect associated with binding CBP than to other enzymes, e.g., enzyme activity inhibition. The specificity is also with respect to other biomolecules (not limited to CBP) that may be present in a particular sample.

[0092] The term "first line cancer therapy" refers to therapy administered to a subject as an initial regimen to reduce the number of cancer cells. First line therapy is also referred to as induction therapy, primary therapy and primary treatment. First-line therapy can be an administered combination with one or more agents. A summary of currently accepted approaches to first line treatment for certain disease can be found in the NCI guidelines for such diseases.

[0093] The term "second line cancer therapy" refers to a cancer treatment that is administered to a subject who does not respond to first line therapy, that is, often first line therapy is administered or who has a recurrence of cancer after being in remission. In certain embodiments, second line therapy that may be administered includes a repeat of the initial successful cancer therapy, which may be any of the treatments described under "first line cancer therapy." A summary of the currently accepted approaches to second line treatment for certain diseases is described in the NCI guidelines for such diseases.

[0094] The term "refractory" refers to circumstances wherein a subject fails to respond or is otherwise resistant to cancer therapy or treatment. The cancer therapy may be first-line, second-line or any subsequently administered treatment. In certain embodiments, refractory refers to a condition where a subject fails to achieve complete remission after two induction attempts. A subject may be refractory due to a cancer cell's intrinsic resistance to a particular therapy, or the subject may be refractory due to an acquired resistance that develops during the course of, or following, a particular therapy.

[0095] In addition, abbreviations as used herein have respective meanings as follows: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] II. Compounds

[0096] Embodiment 1 of this disclosure relates to a compound of I: 1. A compound of Formula I: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics> is a bond or <semantics>−C(R13)2<annotation encoding="application / x-tex">-C(R^{13})_2< / annotation>< / semantics>-; R1 is phenyl, 5-9 membered heteroaryl, C3-C6cycloalkyl, C5-C6cycloalkenyl, 4-9 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups; <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is H, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, or OH; R3 is H, C1-C6alkyl, C1-C6cyanoalkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or 5-6 membered heteroaryl; [Image disponible dans le document PDF, Image available in the PDF document] R5, when attached to carbon, is 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9 membered heteroaryl, 5-6-membered heterocycloalkyl, 4-6 membered cycloalkyl-C1-C6alkyl, [Image disponible dans le document PDF, Image available in the PDF document] , wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9-membered heteroaryl, or 4-6 membered cycloalkyl-C1-C6alkyl are each optionally substituted with one -L2-J1 group and 0-4 J2 groups, provided that J1 is directly bonded to a carbon atom; or R5, when attached to nitrogen, is 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9 membered heteroaryl, or 4-6 membered cycloalkyl-C1-C6alkyl, wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9-membered heteroaryl, or 4-6 membered cycloalkyl- <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl are each optionally substituted with 1 -<semantics>L2<annotation encoding="application / x-tex">L^2< / annotation>< / semantics>-<semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> group and 1-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom; R6 is a five membered heteroaryl containing at least one nitrogen atom, wherein the 5-membered heteroaryl is optionally substituted with 0-2 R8 groups; <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics> is H, halo or <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl; <semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics> is <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl or <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkoxy<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>alkylene; each R10 is independently H, C1-C6alkyl, C1-C6haloalkyl or cyclopropyl; each R11 is independently H, C1-C6alkyl, or C1-C6haloalkyl, or two R11 groups, together with the carbon atom to which both R11 groups are attached, join to form a cyclopropyl group; each R12 is independently H, C1-C6alkyl, C1-C6hydroxyalkyl or C1-C6haloalkyl; each R13 is independently H, CH3, or F, or each R13 join, together with the carbon atom to which they are both attached, to form a C3-C6 cycloalkyl group; [Image disponible dans le document PDF, Image available in the PDF document] <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is cyano, <semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics> alkenyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cyanoalkyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cyanoalkylethynylene, <semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkenyl<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- <semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylene, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylsulfonyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylsulfonyl<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylene, <semantics>−N(R10)2<annotation encoding="application / x-tex">-N(R^{10})_2< / annotation>< / semantics>, di-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkylamino<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- C6alkylene, C1-C6alkylaminoC1-C6alkylene, aminoC1-C6alkylene, -C(O)-C1-C6alkyl, -C(O)-C1- <semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>hydroxyalkyl, <semantics>−C(O)−C1−C6<annotation encoding="application / x-tex">-C(O)-C_1-C_6< / annotation>< / semantics>haloalkyl, <semantics>−C(O)OR12<annotation encoding="application / x-tex">-C(O)OR^{12}< / annotation>< / semantics>, <semantics>−C1−C3<annotation encoding="application / x-tex">-C_1-C_3< / annotation>< / semantics>alkylene-<semantics>−C(O)OR12<annotation encoding="application / x-tex">-C(O)OR^{12}< / annotation>< / semantics>, <semantics>−C(O)−N(H)−C3−C6<annotation encoding="application / x-tex">-C(O)-N(H)-C_3-C_6< / annotation>< / semantics> C6cycloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C6alkylene, C3-C6cycloalkylC2-C6alkynylene, 4-6 memt ered heterocycloalkyl, -C(O)-N(R10)2, -C1-C6alkylene-C(O)-N(R10)2 or phenyl-C1-C6alkoxy, provided that when <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is attached to a nitrogen atom, <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is not cyano; each G2 is independently halo, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, OH, oxo, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>hydroxyalkyl, provided that when <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is attached to a nitrogen atom, <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is not halo, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- C6alkoxy, C1-C6haloalkoxy, or OH; [Image disponible dans le document PDF, Image available in the PDF document] <semantics>−C(O)N(H)−CN<annotation encoding="application / x-tex">-C(O)N(H)-CN< / annotation>< / semantics>, <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>, <semantics>−C(O)N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-C(O)N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alky tetrazolyl, or <semantics>−S(O)2−N(R10)2<annotation encoding="application / x-tex">-S(O)_2-N(R^{10})_2< / annotation>< / semantics>; and each J2 is independently 4-6 membered heterocycloalkyl, -O-(4-6 membered heterocycloalkyl), -O-C3-C6cycloalkyl, C3-C6cycloalkylalkoxy, phenyl-C1-C6alkoxy, C1-C6alkyl, C1-C6alkoxy, halo, C1- C6haloalkyl, C1-C6haloalkoxy, OH, C1-C6hydroxyalkyl, CN, C1-C6cyanoalkyl, C2-C6alkynyl, C3- C6cycloalkylethynylene, C3-C6cycloalkyl, 4-6 membered heterocycloalkyl, NO2, or -N(R10)2, provided that when J2 is attached to nitrogen, J2 is not -O-(4-6 membered heterocycloalkyl), -O-C3-C6cycloalkyl, C3-C6cycloalkylalkoxy, phenyl-C1-C6alkoxy, C1-C6alkoxy, halo, C1-C6haloalkoxy, OH, CN, C2- <semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkynyl, <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cycloalkylethynylene, or -<semantics>N(R10)2<annotation encoding="application / x-tex">N(R^{10})_2< / annotation>< / semantics>.

[0097] The phrase "wherein <semantics>ℝ1<annotation encoding="application / x-tex">\mathbb{R}^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>𝔾1<annotation encoding="application / x-tex">\mathbb{G}^1< / annotation>< / semantics> group and 1-3 <semantics>𝔾2<annotation encoding="application / x-tex">\mathbb{G}^2< / annotation>< / semantics> groups" is intended to include instances where <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> Group; <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is optionally substituted with 1-3 G2 groups, and R1 is optionally substituted with both 1 G1 Group and 1-3 G2 groups. This interpretation applies to all variables described in this disclosure (such as R1, and J1 and J2 with respect to R5) which can be optionally substituted with more than one additional variable (such as G1 and G2 or J1 and <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics>). Subembodiments of Embodiment 1

[0098] Embodiment 1(a1) of this disclosure relates to Embodiment 1, wherein: L is a bond, -CH2- <semantics>CH2<annotation encoding="application / x-tex">CH_{2}< / annotation>< / semantics>-, <semantics>−(CH2)1−2<annotation encoding="application / x-tex">-(CH_{2})_{1-2}< / annotation>< / semantics>-<semantics>CH<annotation encoding="application / x-tex">CH< / annotation>< / semantics>=<semantics>CH<annotation encoding="application / x-tex">CH< / annotation>< / semantics>-<semantics>(CH2)0−1<annotation encoding="application / x-tex">(CH_{2})_{0-1}< / annotation>< / semantics>-, <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^{2}R^{3}< / annotation>< / semantics>-, <semantics>−C(O)<annotation encoding="application / x-tex">-C(O)< / annotation>< / semantics>-, or <semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_{2}< / annotation>< / semantics>-; provided that when <semantics>A1<annotation encoding="application / x-tex">A^{1}< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^{7}< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^{2}< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^{6}< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^{3}< / annotation>< / semantics> is <semantics>−L−R1<annotation encoding="application / x-tex">-L-R^1< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C, then L is a bond.

[0099] Embodiment 1(a2) of this disclosure relates to Embodiment 1, wherein R5, when attached to carbon, is 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9 membered heteroaryl, 5-6- membered heterocycloalkyl <Formule mathématique disponible dans le document PDF, Math available in the PDF document>$\fine C(R^4)_2$-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, or <Formule mathématique disponible dans le document PDF, Math available in the PDF document>$\fine C(O)OR^{14}$, wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, or 5-9-membered heteroaryl are each optionally substituted with one <semantics>−L2−J1<annotation encoding="application / x-tex">-L^2-J^1< / annotation>< / semantics> group and 0-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom; or R5, when attached to nitrogen, is 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, or 5-9 membered heteroaryl wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, or 5-9-membered heteroaryl are each optionally substituted with 1 -L2-J1 group and 1-4 J2 groups, provided that J1 is directly bonded to a carbon atom.

[0100] Embodiment 1(a) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]

[0101] Embodiment 1(b) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]

[0102] Embodiment 1(c) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document]

[0103] Embodiment 1(d) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document]

[0104] Embodiment 1(e) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document]

[0105] Embodiment 1(f) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document]

[0106] Embodiment 1(g) of this disclosure relates to Embodiment 1, wherein: [Image disponible dans le document PDF, Image available in the PDF document]

[0107] Embodiment 1(h) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), or 1(g), wherein L is a bond.

[0108] Embodiment 1(i) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, or <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, wherein L is a bond, or <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0109] Embodiment 1(j) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), or 1(g), wherein L is <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0110] Embodiment 1(j) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), or 1(g), wherein L -(CH2)1-2-CH=CH-(CH2)0-1-.

[0111] Embodiment 1(k) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), or 1(g), wherein L is -C(O)-.

[0112] Embodiment 1(1) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, or <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, wherein L is <semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_2< / annotation>< / semantics>-.

[0113] Embodiment 1(m) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), or 1(l) wherein R1 is phenyl or a 5-9 membered heteroaryl, wherein <semantics>ℝ1<annotation encoding="application / x-tex">\mathbb{R}^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>𝔾1<annotation encoding="application / x-tex">\mathbb{G}^1< / annotation>< / semantics> group and 1-3 <semantics>𝔾2<annotation encoding="application / x-tex">\mathbb{G}^2< / annotation>< / semantics> groups.

[0114] Embodiment 1(o) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), or 1(l), wherein R1 is phenyl optionally substituted with 1 G1 group and <semantics>1−3<annotation encoding="application / x-tex">1-3< / annotation>< / semantics> G2 groups.

[0115] Embodiment 1(p) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), or 1(l), wherein R1 is a 5-9 membered heteroaryl, optionally substituted with 1 G1 group and 1-3 G2 groups.

[0116] Embodiment 1(q) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), <semantics>1(d)<annotation encoding="application / x-tex">1(d)< / annotation>< / semantics>, <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, or <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cycloalkyl or <semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cycloalkenyl, wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> group and 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups.

[0117] Embodiment 1(r) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), or 1(l), wherein R1 is 4-9 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein <semantics>ℝ1<annotation encoding="application / x-tex">\mathbb{R}^1< / annotation>< / semantics> is optionally substituted with <semantics>𝟙<annotation encoding="application / x-tex">\mathbb{1}< / annotation>< / semantics> <semantics>𝔾1<annotation encoding="application / x-tex">\mathbb{G}^1< / annotation>< / semantics> group and <semantics>𝟙<annotation encoding="application / x-tex">\mathbb{1}< / annotation>< / semantics>-<semantics>𝟛<annotation encoding="application / x-tex">\mathbb{3}< / annotation>< / semantics> <semantics>𝔾2<annotation encoding="application / x-tex">\mathbb{G}^2< / annotation>< / semantics> groups.

[0118] Embodiment 1(s) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), 1(l), 1(m), 1(n), 1(o), 1(p), 1(q) or 1(r), wherein R5 is attached to carbon and is 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, 5-9 membered heteroaryl, 5-6-membered heterocycloalkyl, $\frac{\mbox{\colored}}{\mbox{\colored}}$ <semantics>C(R4)2<annotation encoding="application / x-tex">C(R^4)_2< / annotation>< / semantics>-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics> , or $\frac{\mbox{\colored}}{\mbox{\colored}}$ <semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics> wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, or 5-9-membered heteroaryl are each optionally substituted with one <semantics>−L2−J1<annotation encoding="application / x-tex">-L^2-J^1< / annotation>< / semantics> group and <semantics>0−4<annotation encoding="application / x-tex">0-4< / annotation>< / semantics> J2 groups, provided that J1 is directly bonded to a carbon atom.

[0119] Embodiment 1(t) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), 1(e), 1(f), 1(g), 1(h), 1(i), 1(j), 1(k), 1(l), 1(m), 1(n), 1(o), 1(p), 1(q) or 1(r), wherein or R5 is attached to nitrogen and is 4-6 membered cycloalkyl, 5-6 cycloalkenyl, phenyl, or 5-9 membered heteroaryl, wherein the 4-6 membered cycloalkyl, 5-6 membered cycloalkenyl, phenyl, or 5-9-membered heteroaryl are each optionally substituted with <semantics>1−L2−J1<annotation encoding="application / x-tex">1-L^2-J^1< / annotation>< / semantics> group and <semantics>1−4<annotation encoding="application / x-tex">1-4< / annotation>< / semantics> J2 groups, provided that J1 is directly bonded to a carbon atom.

[0015] Embodiment 1(u) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), <semantics>1(d)<annotation encoding="application / x-tex">1(d)< / annotation>< / semantics>, <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^{1}< / annotation>< / semantics> is <semantics>−C(O)OH<annotation encoding="application / x-tex">-C(O)OH< / annotation>< / semantics> or <semantics>−C(O)O−C1−C6<annotation encoding="application / x-tex">-C(O)O-C_1-C_6< / annotation>< / semantics>alkyl.

[0016] Embodiment 1(v) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(o)<annotation encoding="application / x-tex">1(o)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is -C(O)OH.

[0017] Embodiment 1(w) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), <semantics>1(d)<annotation encoding="application / x-tex">1(d)< / annotation>< / semantics>, <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(o)<annotation encoding="application / x-tex">1(o)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^{1}< / annotation>< / semantics> is <semantics>−C(O)O−C1−C6<annotation encoding="application / x-tex">-C(O)O-C_1-C_6< / annotation>< / semantics>alkyl or <semantics>CH2−C(O)O−C1−C6<annotation encoding="application / x-tex">CH_2-C(O)O-C_1-C_6< / annotation>< / semantics>alkyl.

[0018] Embodiment 1(x) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(o)<annotation encoding="application / x-tex">1(o)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(R10)2<annotation encoding="application / x-tex">-C(O)N(R^{10})_2< / annotation>< / semantics>, <semantics>−C(O)N(H)−CN<annotation encoding="application / x-tex">-C(O)N(H)-CN< / annotation>< / semantics> or <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>.

[0019] Embodiment 1(y) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(o)<annotation encoding="application / x-tex">1(o)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-C(O)N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C6<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_6< / annotation>< / semantics>alkyl, <semantics>C1−C6<annotation encoding="application / x-tex">C_1-C_6< / annotation>< / semantics>alkylsulfonyl or <semantics>−S(O)2−N(R10)2<annotation encoding="application / x-tex">-S(O)_2-N(R^{10})_2< / annotation>< / semantics>.

[0020] Embodiment 1(z) of this disclosure relates to Embodiment 1, 1(a1), 1(a2), 1(a), 1(b), 1(c), 1(d), <semantics>1(e)<annotation encoding="application / x-tex">1(e)< / annotation>< / semantics>, <semantics>1(f)<annotation encoding="application / x-tex">1(f)< / annotation>< / semantics>, <semantics>1(g)<annotation encoding="application / x-tex">1(g)< / annotation>< / semantics>, <semantics>1(h)<annotation encoding="application / x-tex">1(h)< / annotation>< / semantics>, <semantics>1(i)<annotation encoding="application / x-tex">1(i)< / annotation>< / semantics>, <semantics>1(j)<annotation encoding="application / x-tex">1(j)< / annotation>< / semantics>, <semantics>1(k)<annotation encoding="application / x-tex">1(k)< / annotation>< / semantics>, <semantics>1(l)<annotation encoding="application / x-tex">1(l)< / annotation>< / semantics>, <semantics>1(m)<annotation encoding="application / x-tex">1(m)< / annotation>< / semantics>, <semantics>1(n)<annotation encoding="application / x-tex">1(n)< / annotation>< / semantics>, <semantics>1(o)<annotation encoding="application / x-tex">1(o)< / annotation>< / semantics>, <semantics>1(p)<annotation encoding="application / x-tex">1(p)< / annotation>< / semantics>, <semantics>1(q)<annotation encoding="application / x-tex">1(q)< / annotation>< / semantics>, <semantics>1(r)<annotation encoding="application / x-tex">1(r)< / annotation>< / semantics>, <semantics>1(s)<annotation encoding="application / x-tex">1(s)< / annotation>< / semantics> or <semantics>1(t)<annotation encoding="application / x-tex">1(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is tetrazolyl.

[0021] Tetrazolyl within the definition of <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is a carboxylic acid isostere, and other carboxylic acid isosteres can be used in its place, such as those described in Figure 25 in Meanwell, Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design, Journal of Medicinal Chemistry, dx.doi.org / 10.1021 / jm1013693.

[0022] In another embodiment of Embodiment 1, J1 can be a carboxylic acid isostere as described in Meanwell.

[0023] Embodiment 2 of this disclosure relates to a compound according to Embodiment 1 or Embodiment 1(a1), wherein: R1 is phenyl, 5-6 membered heteroaryl, C3-C6cycloalkyl, C5-C6cycloalkenyl, 4-6 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups; R3 is H, C1-C6alkyl, C1-C6cyanoalkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or 5-6 membered heteroaryl; <semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics> is H, OH, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>alkyl, or <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>haloalkyl; R5, when attached to carbon, is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6 membered heteroaryl, 5-6-membered heterocycloalkyl, <semantics>ξ<annotation encoding="application / x-tex">\frac{\xi}{}< / annotation>< / semantics> = <semantics>C(R4)2<annotation encoding="application / x-tex">C(R^4)_2< / annotation>< / semantics>-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, or <semantics>ξ<annotation encoding="application / x-tex">\frac{\xi}{}< / annotation>< / semantics> = <semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>. wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6-membered heteroaryl, or 5-6- membered heterocycloalkyl are each optionally substituted with one J1 group and 0-4 J2 groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom; or R5, when attached to nitrogen, is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6 membered heteroaryl, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6-membered heteroaryl are each optionally substituted with <semantics>1−L2−J1<annotation encoding="application / x-tex">1 - L^2 - J^1< / annotation>< / semantics> group and <semantics>1−4J2<annotation encoding="application / x-tex">1-4 J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom; R6 is a five membered heteroaryl containing at least one nitrogen atom, wherein the heteroaryl is optionally substituted with 1-2 R8 groups; <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics> is H, halo or <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkyl; <semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics> is <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>alkyl or <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>alkoxy<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>alkylene; each R10 is independently H, C1-C5alkyl, C1-C5haloalkyl or cyclopropyl; each R11 is independently H, C1-C5alkyl, or C1-C5haloalkyl, or two R11 groups, together with the carbon atom to which both R11 groups are attached, join to form a cyclopropyl group; each R12 is H; G1 is CN, C1-C6cyanoalkyl, C1-C5cyanoalkylethynylene, C2-C5alkenylC1-C5alkylene, C1- C5alkylsulfonyl, C1-C5alkylsulfonylC1-C5alkylene, -N(R10)2, di-C1-C5alkylamino-C1-C5alkylene, C1- C5alkylamino-C1-C5alkylene, aminoC1-C5alkylene, -C(O)-C1-C5alkyl, -C(O)-C1-C5hydroxyalkyl, -C(O)- C1-C5haloalkyl, -C(O)OR12, -C1-C3alkylene-C(O)OR12, -C(O)-N(H)-C3-C6cycloalkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C5alkylene, C3-C6cycloalkylC2-C5alkynylene, 4-6 membered heterocycloalkyl, -C(O)- <semantics>N(R10)2<annotation encoding="application / x-tex">N(R^{10})_2< / annotation>< / semantics>, <semantics>−C1<annotation encoding="application / x-tex">-C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkylene-<semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>-<semantics>N(R10)2<annotation encoding="application / x-tex">N(R^{10})_2< / annotation>< / semantics> or phenyl-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkoxy, provided that when <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is attached to a nitrogen atom, G1 is not CN; each G2 is independently CN, halo, C1-C5alkyl, C1-C5haloalkyl, C1-C5alkoxy, C1-C5haloalkoxy, OH, oxo, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>hydroxyalkyl, provided that when <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is attached to a nitrogen atom, <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is not CN, halo, C1-C5 alkoxy, C1-C5haloalkoxy, or OH; [Image disponible dans le document PDF, Image available in the PDF document] <semantics>−C(O)N(H)−CN<annotation encoding="application / x-tex">-C(O)N(H)-CN< / annotation>< / semantics>, <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>, <semantics>−C(O)N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-C(O)N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alky tetrazolyl, or <semantics>−S(O)2−N(R10)2<annotation encoding="application / x-tex">-S(O)_2-N(R^{10})_2< / annotation>< / semantics>; and each J2 is independently 4-6 membered heterocycloalkyl, -O-(4-6 membered heterocycloalkyl), -O-C3-C6cycloalkyl, C3-C6cycloalkylalkoxy, phenyl-C1-C5alkoxy, C1-C5alkyl, C1-C5alkoxy, halo, C1- C5haloalkyl, C1-C5haloalkoxy, OH, C1-C5hydroxyalkyl, CN, C1-C5cyanoalkyl, C2-C5alkynyl, C3- C6cycloalkylethynylene, C3-C6cycloalkyl, 4-6 membered heterocycloalkyl, or -N(R10)2, provided that when J2 is attached to nitrogen, J2 is not -O-(4-6 membered heterocycloalkyl), -O-C3-C6cycloalkyl, C3- C6cycloalkylalkoxy, phenyl-C1-C5alkoxy, C1-C5alkoxy, halo, C1-C5haloalkoxy, OH, CN, C2-C6alkynyl, <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>cycloalkylethynylene, or -<semantics>N(R10)2<annotation encoding="application / x-tex">N(R^{10})_2< / annotation>< / semantics>. Subembodiments of Embodiment 2

[0129] Embodiment 2(a) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-R1, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is C, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is N; or <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-R1, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C; or <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is -L-R1, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C.

[0130] Embodiment 2(b) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-R1, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C; or <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is -L-R1, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C.

[0131] Embodiment 2(c) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-<semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is C, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is N.

[0132] Embodiment 2(d) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-<semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is C, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C.

[0133] Embodiment 2(e) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is absent, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is -L-R1, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is C, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is N, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C.

[0134] Embodiment 2(f) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^{1}< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^{7}< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^{2}< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^{6}< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^{3}< / annotation>< / semantics> is -L-<semantics>R1<annotation encoding="application / x-tex">R^{1}< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^{4}< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^{5}< / annotation>< / semantics>, <semantics>X1<annotation encoding="application / x-tex">X^{1}< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^{2}< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^{3}< / annotation>< / semantics> is C.

[0135] Embodiment 2(g) of this disclosure relates to Embodiment 2, wherein: <semantics>A1<annotation encoding="application / x-tex">A^1< / annotation>< / semantics> is <semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>, <semantics>A2<annotation encoding="application / x-tex">A^2< / annotation>< / semantics> is <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>, <semantics>A3<annotation encoding="application / x-tex">A^3< / annotation>< / semantics> is <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>, <semantics>A4<annotation encoding="application / x-tex">A^4< / annotation>< / semantics> is -L-R1, <semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics> is N, <semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics> is C, and <semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics> is C.

[0136] Embodiment 2(h) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or 2(g), wherein L is a bond.

[0137] Embodiment 2(i) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, wherein L is a bond, or <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0138] Embodiment 2(j) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, wherein L is <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0139] Embodiment 2(j) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, wherein L -<semantics>(CH2)1−2<annotation encoding="application / x-tex">(CH_2)_{1-2}< / annotation>< / semantics>-<semantics>CH=CH−(CH2)0−1<annotation encoding="application / x-tex">CH=CH-(CH_2)_{0-1}< / annotation>< / semantics>-.

[0140] Embodiment 2(k) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, wherein L is -C(O)-.

[0141] Embodiment 2(1) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), or <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, wherein L is <semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_2< / annotation>< / semantics>-.

[0142] Embodiment 2(m) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), or 2(l), wherein R1 is phenyl or a 5-6 membered heteroaryl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0143] Embodiment 2(o) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), or 2(l), wherein R1 is phenyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0144] Embodiment 2(p) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), or 2(l), wherein R1 is a 5-6 membered heteroaryl, optionally substituted with 1 G1 group and 1-3 G2 groups.

[0145] Embodiment 2(q) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), or 2(l), wherein R1 is C3-C6cycloalkyl or C5-C6cycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0146] Embodiment 2(r) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), or 2(l), wherein R1 is 4-9 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0147] Embodiment 2(s) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), 2(l), 2(m), 2(n), 2(o), 2(p), 2(q) or 2(r), wherein R5 is attached to carbon and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6 membered heteroaryl, 5- 6-membered heterocycloalkyl, <semantics>ξζ<annotation encoding="application / x-tex">\frac{\xi}{\zeta}< / annotation>< / semantics> = <semantics>C(R4)2<annotation encoding="application / x-tex">C(R^4)_2< / annotation>< / semantics>-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, or <semantics>ξζ<annotation encoding="application / x-tex">\frac{\xi}{\zeta}< / annotation>< / semantics> = <semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6-membered heteroaryl, or 5-6-membered heterocycloalkyl are each optionally substituted with one <semantics>−L2−J1<annotation encoding="application / x-tex">-L^2-J^1< / annotation>< / semantics> group and 0-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom.

[0148] Embodiment 2(t) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), 2(l), 2(m), 2(n), 2(o), 2(p), 2(q) or 2(r), wherein or R5 is attached to nitrogen and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6 membered heteroaryl, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6-membered heteroaryl are each optionally substituted with <semantics>1−L2−J1<annotation encoding="application / x-tex">1 - L^2 - J^1< / annotation>< / semantics> group and <semantics>1−4J2<annotation encoding="application / x-tex">1 - 4 J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom.

[0149] Embodiment 2(u) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>2(h)<annotation encoding="application / x-tex">2(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^{1}< / annotation>< / semantics> is -C(O)OH or <semantics>−C(O)O−C1−C5<annotation encoding="application / x-tex">-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl.

[0150] Embodiment 2(v) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>2(h)<annotation encoding="application / x-tex">2(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is -C(O)OH.

[0151] Embodiment 2(w) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>Ω(h)<annotation encoding="application / x-tex">\Omega(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)O−C1−C1<annotation encoding="application / x-tex">-C(O)O-C_1-C_1< / annotation>< / semantics> <semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkyl or <semantics>−CH2<annotation encoding="application / x-tex">-CH_2< / annotation>< / semantics>-<semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkyl.

[0152] Embodiment 2(x) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>2(h)<annotation encoding="application / x-tex">2(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(R10)2<annotation encoding="application / x-tex">-C(O)N(R^{10})_2< / annotation>< / semantics>, <semantics>−C(O)N(H)−CN<annotation encoding="application / x-tex">-C(O)N(H)-CN< / annotation>< / semantics> or <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>.

[0153] Embodiment 2(y) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>2(h)<annotation encoding="application / x-tex">2(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(H)<annotation encoding="application / x-tex">-C(O)N(H)< / annotation>< / semantics>- <semantics>SO2<annotation encoding="application / x-tex">SO_2< / annotation>< / semantics>-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkyl, -N(H)-<semantics>SO2<annotation encoding="application / x-tex">SO_2< / annotation>< / semantics>-<semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>alkylsulfonyl or -S(O)2-N(R10)2.

[0154] Embodiment 2(z) of this disclosure relates to Embodiment 2, 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), <semantics>2(g)<annotation encoding="application / x-tex">2(g)< / annotation>< / semantics>, <semantics>2(h)<annotation encoding="application / x-tex">2(h)< / annotation>< / semantics>, <semantics>2(i)<annotation encoding="application / x-tex">2(i)< / annotation>< / semantics>, <semantics>2(j)<annotation encoding="application / x-tex">2(j)< / annotation>< / semantics>, <semantics>2(k)<annotation encoding="application / x-tex">2(k)< / annotation>< / semantics>, <semantics>2(l)<annotation encoding="application / x-tex">2(l)< / annotation>< / semantics>, <semantics>2(m)<annotation encoding="application / x-tex">2(m)< / annotation>< / semantics>, <semantics>2(n)<annotation encoding="application / x-tex">2(n)< / annotation>< / semantics>, <semantics>2(o)<annotation encoding="application / x-tex">2(o)< / annotation>< / semantics>, <semantics>2(p)<annotation encoding="application / x-tex">2(p)< / annotation>< / semantics>, <semantics>2(q)<annotation encoding="application / x-tex">2(q)< / annotation>< / semantics>, <semantics>2(r)<annotation encoding="application / x-tex">2(r)< / annotation>< / semantics>, <semantics>2(s)<annotation encoding="application / x-tex">2(s)< / annotation>< / semantics> or <semantics>2(t)<annotation encoding="application / x-tex">2(t)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is tetrazolyl.

[0155] Embodiment 3 of this disclosure relates to a compound according to Embodiment 1 or 2 having Formula II(a), II(b) or II(c) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof. Subembodiments of Embodiment 3

[0156] Embodiment 3(a1) of this disclosure relates to Embodiment 3 having Formula II(a) or II(b).

[0157] Embodiment 3(a) of this disclosure relates to Embodiment 3 having Formula II(a).

[0158] Embodiment 3(b) of this disclosure relates to Embodiment 3 having Formula II(b).

[0159] Embodiment 3(c) of this disclosure relates to Embodiment 3 having Formula II(c).

[0160] Embodiment 3(d) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), or 3(c), wherein L is a bond.

[0161] Embodiment 3(e) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), or 3(c), wherein L is a bond, or <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0162] Embodiment 3(f) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), or 3(c), wherein L is <semantics>−CR2R3<annotation encoding="application / x-tex">-CR^2R^3< / annotation>< / semantics>-.

[0163] Embodiment 3(g) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), or 3(f), wherein R1 is phenyl or a 5-6 membered heteroaryl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0164] Embodiment 3(h) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), or 3(f), wherein R1 is phenyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0165] Embodiment 3(i) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), or 3(f), wherein R1 is a 5-6 membered heteroaryl, optionally substituted with 1 G1 group and 1-3 G2 groups.

[0166] Embodiment 3(j) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), or 3(f), wherein R1 is C3-C6cycloalkyl or C5-C6cycloalkenyl, wherein R1 is optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> group and 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups.

[0167] Embodiment 3(k) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), or 3(f), wherein R1 is 4-9 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0168] Embodiment 3(1) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), 3(f), 3(g), 3(h), 3(i), 3(j), or 3(k), wherein R5 is attached to carbon and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6 membered heteroaryl, 5-6-membered heterocycloalkyl, <semantics>C(R4)2<annotation encoding="application / x-tex">C(R^4)_2< / annotation>< / semantics>-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics> or <semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6-membered heteroaryl, or 5-6-membered heterocycloalkyl are each optionally substituted with one <semantics>−L2−J1<annotation encoding="application / x-tex">-L^2-J^1< / annotation>< / semantics> group and 0-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom.

[0169] Embodiment 3(m) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), 3(f), 3(g), 3(h), 3(i), 3(j), or 3(k), wherein or R5 is attached to nitrogen and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6 membered heteroaryl, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6-membered heteroaryl are each optionally substituted with 1 -L2-J1 group and 1-4 J2 groups, provided that J1 is directly bonded to a carbon atom.

[0170] Embodiment 3(n) of this disclosure relates to 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), 3(f), 3(g), <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)OH<annotation encoding="application / x-tex">-C(O)OH< / annotation>< / semantics> or <semantics>−C(O)O−C1−C5<annotation encoding="application / x-tex">-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl.

[0171] Embodiment 3(o) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), <semantics>3(f)<annotation encoding="application / x-tex">3(f)< / annotation>< / semantics>, <semantics>3(g)<annotation encoding="application / x-tex">3(g)< / annotation>< / semantics>, <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is -C(O)OH.

[0172] Embodiment 3(p) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), <semantics>3(f)<annotation encoding="application / x-tex">3(f)< / annotation>< / semantics>, <semantics>3(g)<annotation encoding="application / x-tex">3(g)< / annotation>< / semantics>, <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)O−C1−C5<annotation encoding="application / x-tex">-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl or <semantics>−CH2−C(O)O−C1−C5<annotation encoding="application / x-tex">-CH_2-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl.

[0173] Embodiment 3(q) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), <semantics>3(f)<annotation encoding="application / x-tex">3(f)< / annotation>< / semantics>, <semantics>3(g)<annotation encoding="application / x-tex">3(g)< / annotation>< / semantics>, <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(R10)2<annotation encoding="application / x-tex">-C(O)N(R^{10})_2< / annotation>< / semantics>, <semantics>−C(O)N(H)<annotation encoding="application / x-tex">-C(O)N(H)< / annotation>< / semantics>-CN or <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>.

[0174] Embodiment 3(r) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), <semantics>3(f)<annotation encoding="application / x-tex">3(f)< / annotation>< / semantics>, <semantics>3(g)<annotation encoding="application / x-tex">3(g)< / annotation>< / semantics>, <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-C(O)N(H)-SO_2-C_1-C_5< / annotation>< / semantics> alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics> C5alkyl, C1-C5alkylsulfonyl or -S(O)2-N(<semantics>ℝ10<annotation encoding="application / x-tex">\mathbb{R}^{10}< / annotation>< / semantics>)2.

[0175] Embodiment 3(s) of this disclosure relates to Embodiment 3, 3(a1), 3(a), 3(b), 3(c), 3(d), 3(e), <semantics>3(f)<annotation encoding="application / x-tex">3(f)< / annotation>< / semantics>, <semantics>3(g)<annotation encoding="application / x-tex">3(g)< / annotation>< / semantics>, <semantics>3(h)<annotation encoding="application / x-tex">3(h)< / annotation>< / semantics>, <semantics>3(i)<annotation encoding="application / x-tex">3(i)< / annotation>< / semantics>, <semantics>3(j)<annotation encoding="application / x-tex">3(j)< / annotation>< / semantics>, <semantics>3(k)<annotation encoding="application / x-tex">3(k)< / annotation>< / semantics>, <semantics>3(l)<annotation encoding="application / x-tex">3(l)< / annotation>< / semantics>, or <semantics>3(m)<annotation encoding="application / x-tex">3(m)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is tetrazolyl.

[0176] Embodiment 4 of this disclosure relates to a compound according to any one of Embodiments 1-3, including any subembodiments thereof, having any one of Formulae III(a) – III(f): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] > > or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog therec f. Subembodiments of Embodiment 4

[0177] Embodiment 4(a1) of this disclosure relates to Embodiment 4 having any one of formulae III(a), III(c), III(d), III(e) or III(f).

[0178] Embodiment 4(a2) of this disclosure relates to Embodiment 4 having any one of formulae III(a), III(c) or III(d).

[0179] Embodiment 4(a) of this disclosure relates to Embodiment 4 having any one of formulae III(a), III(b), III(c) or III(d).

[0180] Embodiment 4(b) of this disclosure relates to Embodiment 4 having any one of formulae III(e) or III(f).

[0181] Embodiment 4(c) of this disclosure relates to Embodiment 4 having formula III(a).

[0182] Embodiment 4(d) of this disclosure relates to Embodiment 4 having formula III(b).

[0183] Embodiment 4(e) of this disclosure relates to Embodiment 4 having formula III(c).

[0184] Embodiment 4(f) of this disclosure relates to Embodiment 4 having formula III(d).

[0185] Embodiment 4(g) of this disclosure relates to Embodiment 4 having formula III(e).

[0186] Embodiment 4(h) of this disclosure relates to Embodiment 4 having formula III(f).

[0187] Embodiment 4(i) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, or <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics> wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is phenyl or a 5-6 membered heteroaryl, wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0188] Embodiment 4(j) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(g), or 4(h), wherein R1 is phenyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0189] Embodiment 4(k) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(g), or 4(h), wherein R1 is a 5-6 membered heteroaryl, optionally substituted with 1 G1 group and 1-3 G2 groups.

[0190] Embodiment 4(1) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(g), or 4(h), wherein R1 is C3-C6cycloalkyl or C5-C6cycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0191] Embodiment 4(m) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(g), or 4(h), wherein R1 is 4-9 membered heterocycloalkyl, or 5-6 membered heterocycloalkenyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0192] Embodiment 4(n) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(g), 4(h), 4(i), 4(j), 4(k), 4(l), or 4(m), wherein R5 is attached to carbon and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6 membered heteroaryl, 5-6-membered heterocycloalkyl, <semantics>C(R4)2<annotation encoding="application / x-tex">C(R^4)_2< / annotation>< / semantics>-<semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, or <semantics>C(O)OR14<annotation encoding="application / x-tex">C(O)OR^{14}< / annotation>< / semantics>, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, 5-6-membered heteroaryl, or 5-6-membered heterocycloalkyl are each optionally substituted with one <semantics>−L2−J1<annotation encoding="application / x-tex">-L^2-J^1< / annotation>< / semantics> group and 0-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom.

[0193] Embodiment 4(o) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, or <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, wherein or <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics> is attached to nitrogen and is 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6 membered heteroaryl, wherein the 4-6 membered cycloalkyl, cyclohexenyl, phenyl, or 5-6-membered heteroaryl are each optionally substituted with 1 -L2- <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> group and 1-4 <semantics>J2<annotation encoding="application / x-tex">J^2< / annotation>< / semantics> groups, provided that <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is directly bonded to a carbon atom.

[0194] Embodiment 4(p) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), <semantics>4(d)<annotation encoding="application / x-tex">4(d)< / annotation>< / semantics>, <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, <semantics>4(n)<annotation encoding="application / x-tex">4(n)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^{1}< / annotation>< / semantics> is -C(O)OH or -C(O)O-C1- C₅alkyl.

[0195] Embodiment 4(q) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), <semantics>4(d)<annotation encoding="application / x-tex">4(d)< / annotation>< / semantics>, <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, <semantics>4(n)<annotation encoding="application / x-tex">4(n)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^{1}< / annotation>< / semantics> is -C(O)OH.

[0196] Embodiment 4(r) of this disclosure relates to Embodiment 4, 4(a1), 4(a), 4(b), 4(c), 4(d), 4(e), <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, <semantics>4(n)<annotation encoding="application / x-tex">4(n)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)O−C1−C5<annotation encoding="application / x-tex">-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl or <semantics>−CH2−C(O)O−C1−C5<annotation encoding="application / x-tex">-CH_2-C(O)O-C_1-C_5< / annotation>< / semantics>alkyl.

[0197] Embodiment 4(s) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(R10)2<annotation encoding="application / x-tex">-C(O)N(R^{10})_2< / annotation>< / semantics>, <semantics>−C(O)N(H)−CN<annotation encoding="application / x-tex">-C(O)N(H)-CN< / annotation>< / semantics> or <semantics>−C(O)N(H)OH<annotation encoding="application / x-tex">-C(O)N(H)OH< / annotation>< / semantics>.

[0198] Embodiment 4(t) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), 4(d), <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is <semantics>−C(O)N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-C(O)N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>−N(H)−SO2−C1−C5<annotation encoding="application / x-tex">-N(H)-SO_2-C_1-C_5< / annotation>< / semantics>alkyl, <semantics>C1−C5<annotation encoding="application / x-tex">C_1-C_5< / annotation>< / semantics>alkylsulfonyl or <semantics>−S(O)2−N(R10)2<annotation encoding="application / x-tex">-S(O)_2-N(R^{10})_2< / annotation>< / semantics>.

[0199] Embodiment 4(u) of this disclosure relates to Embodiment 4, 4(a1), 4(a2), 4(a), 4(b), 4(c), <semantics>4(d)<annotation encoding="application / x-tex">4(d)< / annotation>< / semantics>, <semantics>4(e)<annotation encoding="application / x-tex">4(e)< / annotation>< / semantics>, <semantics>4(f)<annotation encoding="application / x-tex">4(f)< / annotation>< / semantics>, <semantics>4(g)<annotation encoding="application / x-tex">4(g)< / annotation>< / semantics>, <semantics>4(h)<annotation encoding="application / x-tex">4(h)< / annotation>< / semantics>, <semantics>4(i)<annotation encoding="application / x-tex">4(i)< / annotation>< / semantics>, <semantics>4(j)<annotation encoding="application / x-tex">4(j)< / annotation>< / semantics>, <semantics>4(k)<annotation encoding="application / x-tex">4(k)< / annotation>< / semantics>, <semantics>4(l)<annotation encoding="application / x-tex">4(l)< / annotation>< / semantics>, <semantics>4(m)<annotation encoding="application / x-tex">4(m)< / annotation>< / semantics>, <semantics>4(n)<annotation encoding="application / x-tex">4(n)< / annotation>< / semantics>, or <semantics>4(o)<annotation encoding="application / x-tex">4(o)< / annotation>< / semantics>, wherein <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is tetrazolyl.

[0200] Embodiment 5 of this disclosure relates to a compound according to any one of Embodiments 1-4, including any subembodiments thereof, wherein R6 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0201] Embodiment 6 of this disclosure relates to a compound according to any one of Embodiments 1-5, including any subembodiments thereof, wherein <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics> is: [Image disponible dans le document PDF, Image available in the PDF document] Subembodiments of Embodiment 6:

[0202] Embodiment 6(a) of this disclosure relates to Embodiment 6, wherein <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics> is: [Image disponible dans le document PDF, Image available in the PDF document]

[0203] Embodiment 6(b) of this disclosure relates to Embodiment 6, wherein R6 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0204] Embodiment 6(c) of this disclosure relates to Embodiment 6, wherein <semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics> is: [Image disponible dans le document PDF, Image available in the PDF document]

[0205] Embodiment 7 of this disclosure relates to a compound according to any one of Embodiments 1-6, including any subembodiments thereof, wherein R4 is H, OH, CF3, or CH3. Subembodiments of Embodiment 7

[0206] Embodiment 7(a) of this disclosure relates to Embodiment 7 wherein R4 is H, CF3, or CH3.

[0207] Embodiment 7(b) of this disclosure relates to Embodiment 7 wherein R4 is H.

[0208] Embodiment 7(c) of this disclosure relates to Embodiment 7 wherein R4 is CF3, or CH3.

[0209] Embodiment 7(d) of this disclosure relates to Embodiment 7 wherein R4 is CH3.

[0210] Embodiment 8 of this disclosure relates to a compound according to any one of Embodiments 1, 2, 3, 5, 6, or 7, including any subembodiments thereof where applicable, wherein L is a bond, -CH2-, -(CH2)2-, CH(CH3)-, CH(CH2CH3)-, -C(O)-, -CH(C3-C6cycloalkyl)-, -CH(pyridyl)-, -C(CH3)(pyridyl)-, <semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_2< / annotation>< / semantics>-, or <semantics>−C(H)(CH2CN)<annotation encoding="application / x-tex">-C(H)(CH_2CN)< / annotation>< / semantics>-. The term "where applicable" as used in the Embodiments and Subembodiments of this disclosure is meant to exclude inapplicable instances where a previous subembodiment is narrower in scope than the later embodiment. For example, Embodiment 8 is broader in scope than embodiments 2(h)-2(l), so Embodiment 8 cannot be applied to Subembodiments <semantics>2(h)−2(1)<annotation encoding="application / x-tex">2(h) - 2(1)< / annotation>< / semantics>. This interpretation of the Embodiment and Subembodiments in this disclosure applies to all instances whether or not the term "where applicable" is used. Subembodiments of Embodiment 8

[0211] Embodiment 8(a) of this disclosure relates to Embodiment 8 wherein L is a bond.

[0212] Embodiment 8(b) of this disclosure relates to Embodiment 8 wherein L is -CH2-, -(CH2)2-, <semantics>CH(CH3)<annotation encoding="application / x-tex">CH(CH_3)< / annotation>< / semantics>-, or <semantics>CH(CH2CH3)<annotation encoding="application / x-tex">CH(CH_2CH_3)< / annotation>< / semantics>-.

[0213] Embodiment 8(c) of this disclosure relates to Embodiment 8 wherein L is -C(O)- or -S(O)2-.

[0214] Embodiment 8(d) of this disclosure relates to Embodiment 8 wherein L is -CH(C3- C6cycloalkyl)-.

[0215] Embodiment 8(e) of this disclosure relates to Embodiment 8 wherein L is -CH(pyridyl)-or -C(CH3)(pyridyl)-.

[0216] Embodiment 8(f) of this disclosure relates to Embodiment 8 wherein L is <semantics>−C(H)(CH2CN)−.<annotation encoding="application / x-tex">-C(H)(CH_2CN)-.< / annotation>< / semantics>

[0217] Embodiment 9 of this disclosure relates to a compound according to any one of Embodiments 1-8, including any subembodiments thereof where applicable, wherein R1 is phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazolyl, C3-C6 cycloalkyl, cyclohexenyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydro-2H-furanyl, oxetanyl, azetidine, tetrahydro-2H-pyranyl, tetrahydro-2H- thiopyranyl 1,1-dioxide, tetrahydro-2H-thiopyranyl 1-oxide, tetrahydro-2H-thiopyranyl, tetrahydrothienyl, or thienyl, wherein <semantics>ℝ1<annotation encoding="application / x-tex">\mathbb{R}^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>𝔾1<annotation encoding="application / x-tex">\mathbb{G}^1< / annotation>< / semantics> group and 1-3 <semantics>𝔾2<annotation encoding="application / x-tex">\mathbb{G}^2< / annotation>< / semantics> groups. Subembodiments of Embodiment 9

[0218] Embodiment 9(a) of this disclosure relates to Embodiment 9 wherein R1 is phenyl, pyridyl, or pyrimidinyl, wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> group and 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups.

[0219] Embodiment 9(b) of this disclosure relates to Embodiment 9 wherein R1 is C3-C6 cycloalkyl or cyclohexynyl, wherein R1 is optionally substituted with 1 G1 group and 1-3 G2 groups.

[0220] Embodiment 9(c) of this disclosure relates to Embodiment 9 wherein R1 is morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydro-2H-furanyl, tetrahydro-2H-pyranyl, tetrahydro-2H- thiopyranyl 1,1-dioxide, tetrahydro-2H-thiopyranyl 1-oxide, tetrahydro-2H-thiopyranyl, or tetrahydrothiophenyl, wherein <semantics>ℝ1<annotation encoding="application / x-tex">\mathbb{R}^1< / annotation>< / semantics> is optionally substituted with <semantics>𝟙𝔾1<annotation encoding="application / x-tex">\mathbb{1} \, \mathbb{G}^1< / annotation>< / semantics> group and 1-3 <semantics>𝔾2<annotation encoding="application / x-tex">\mathbb{G}^2< / annotation>< / semantics> groups.

[0221] Embodiment 9(d) of this disclosure relates to Embodiment 9 wherein R1 is phenyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0222] Embodiment 9(f) of this disclosure relates to Embodiment 9 wherein R1 is pyridyl, optionally substituted with 1 G1 group and 1-3 G2 groups.

[0223] Embodiment 9(g) of this disclosure relates to Embodiment 9 wherein R1 is pyrimidinyl, optionally substituted with <semantics>1G1<annotation encoding="application / x-tex">1 G^1< / annotation>< / semantics> group and <semantics>1−3G2<annotation encoding="application / x-tex">1-3 G^2< / annotation>< / semantics> groups.

[0224] Embodiment 9(h) of this disclosure relates to Embodiment 9 wherein <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics> cycloalkyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0225] Embodiment 9(j) of this disclosure relates to Embodiment 9 wherein R1 is morpholinyl optionally substituted with <semantics>1G1<annotation encoding="application / x-tex">1 G^1< / annotation>< / semantics> group and <semantics>1−3G2<annotation encoding="application / x-tex">1-3 G^2< / annotation>< / semantics> groups.

[0226] Embodiment 9(k) of this disclosure relates to Embodiment 9 wherein R1 is piperazinyl optior ally substituted with <semantics>1G1<annotation encoding="application / x-tex">1 G^1< / annotation>< / semantics> group and <semantics>1−3G2<annotation encoding="application / x-tex">1-3 G^2< / annotation>< / semantics> groups.

[0227] Embodiment 9(1) of this disclosure relates to Embodiment 9 wherein R1 is piperidinyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0228] Embodiment 9(m) of this disclosure relates to Embodiment 9 wherein R1 is pyrrolidinyl optionally substituted with <semantics>1G1<annotation encoding="application / x-tex">1 G^1< / annotation>< / semantics> group and <semantics>1−3G2<annotation encoding="application / x-tex">1-3 G^2< / annotation>< / semantics> groups.

[0229] Embodiment 9(n) of this disclosure relates to Embodiment 9 wherein R1 is tetrahydro-2H- furanyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0230] Embodiment 9(o) of this disclosure relates to Embodiment 9 wherein R1 is tetrahydro-2H- pyranyl optionally substituted with 1 G1 group and 1-3 G2 groups.

[0231] Embodiment 9(p) of this disclosure relates to Embodiment 9 wherein R1 is tetrahydro-2H- thiopyranyl optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> group and 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups.

[0232] Embodiment 10 of this disclosure relates to a compound according to any one of Embodiments 1-9, including any subembodiments thereof where applicable, wherein: R1 is one of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), or (m): (a) <semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics> cycloalkyl optionally substituted with 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups, wherein <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is F, cyano, or <semantics>−CH2CN<annotation encoding="application / x-tex">-CH_2CN< / annotation>< / semantics>; (b) phenyl optionally substituted with 1 <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> group and 1-3 <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> groups, wherein <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is benzyloxy, -C(=CH2)CH3, -C(O)OH, -C(O)NH2, -C(O)N(H)-cyclopropyl, cyclopropyl, cyano, or -SO2CH3; and each G2 is independently -OCHF2, Cl, F, -OCH3, -OCF3, CH3, CF3, and <semantics>−C(CH3)2−OH;<annotation encoding="application / x-tex">-C(CH_3)_2-OH;< / annotation>< / semantics> (c) pyridyl optionally substituted with <semantics>1G1<annotation encoding="application / x-tex">1 G^1< / annotation>< / semantics> group and <semantics>1−2G2<annotation encoding="application / x-tex">1-2 G^2< / annotation>< / semantics> groups, wherein <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics> is -C(O)OH, -C(O)NH2, cyclopropyl, or cyclopropylalkynylene; and each <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics> is independently F, CN, OCH3, CF3, CH3, OH, <semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>CH(CH3)2, and Cl; (d) pyrazolyl optionally substituted with 1 G1 group and 1-2 G2 groups, provided that L is a bond when <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics> is pyrazolyl, wherein <semantics>G1<annotation encoding="application / x-tex">G^1< / annotation>< / semantics>, which can substitute a hydrogen atom of <semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>- or <semantics>=CH<annotation encoding="application / x-tex">=CH< / annotation>< / semantics>-, is -CH2-SO2-CH3, -(CH2)2-N(CH3)2, cyclopropyl, -CH2-cyclopropyl, -(CH2)2-CN, or <semantics>−CH2C(O)N(CH3)2<annotation encoding="application / x-tex">-CH_2C(O)N(CH_3)_2< / annotation>< / semantics>; and each <semantics>G2<annotation encoding="application / x-tex">G^2< / annotation>< / semantics>, which can substitute a hydrogen atom of -NH- or =CH-, is independently C1-C6alkyl, C1-C6haloalkyl, and hydroxyC1-C6alkyl; (e) pyrimidinyl optionally substituted with -NH2, -N(CH3)2, OCH3, n-azetdinyl or cyclopropyl; (f) pyridazinyl; (g) tetrahydro-2H-pyranyl optionally substituted with 1-2 groups each independently <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, C1-C6haloalkyl, hydroxyC1-C6alkyl, Cl and F; (h) tetrahydro-2H-furanyl optionally substituted with 1-2 groups each independently <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, C1-C6haloalkyl, hydroxyC1-C6alkyl, Cl and F; (i) morpholinyl optionally substituted with 1-2 groups each independently <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- C6haloalkyl, and hydroxyC1-C6alkyl; (j) oxetanyl; (k) piperidinyl optionally substituted with 1-2 groups each independently <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>-<semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>alkyl, <semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>- C6haloalkyl, and hydroxyC1-C6alkyl; (1) cyclohexenyl optionally substituted with 1-2 groups each independently C1-C6alkyl, C1- C6haloalkyl, hydroxyC1-C6alkyl, Cl and F; or (m) thienyl. Subembodiments of Embodiment 10

[0233] Embodiment 11 of this disclosure relates to a compound according to any one of Embodiments 1-7, including any subembodiments thereof where applicable, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 2 wherein: G3 is H, OCH3, N-azetidinyl, NH2, -N(CH3)2, cyclopropyl; [Image disponible dans le document PDF, Image available in the PDF document] cyclopropyl, -CH2-cyclopropyl, -(CH2)2-CN, or -CH2C(O)N(CH3)2; <semantics>G5<annotation encoding="application / x-tex">G^5< / annotation>< / semantics> is H or OH; G6 is H or CH3; and [Image disponible dans le document PDF, Image available in the PDF document] -CH2C(CH3)2(OH), cyclopropyl, -CH2-cyclopropyl, -(CH2)2-CN, -CH2C(O)N(CH3)2, -C(O)OC(CH3)3, <semantics>−C(O)CH3<annotation encoding="application / x-tex">-C(O)CH_3< / annotation>< / semantics>, or <semantics>−C(O)C(CH3)3<annotation encoding="application / x-tex">-C(O)C(CH_3)_3< / annotation>< / semantics>. Subembodiments of Embodiment 11

[0234] Embodiment 11(a) of this disclosure relates to Embodiment 11, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0235] Embodiment 11(b) of this disclosure relates to Embodiment 11, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0236] Embodiment 11(c) of this disclosure relates to Embodiment 11, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0237] Embodiment 11(d) of this disclosure relates to Embodiment 11, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0238] Embodiment 12 of this disclosure relates to a compound according to Embodiment 11, including any subembodiments thereof where applicable, wherein: G1 is benzyloxy, -C(=CH2)CH3, -C(O)OH, -C(O)NH2, -C(O)N(H)-cyclopropyl, cyclopropyl, -CH2-cyclopropyl, cyclopropylalkynylene, -CH2-SO2-CH3, -SO2-CH3, -(CH2)N(CH3)2, -(CH2)2-N(CH3)2, -CH2-cyclopropyl, -(CH2)2-CN, -C(O)OC(CH3)3, -C(O)CH3, and -C(O)C(CH3)3, -CH2C(O)N(CH3)2, cyano, or -SO2CH3; and each G2 is independently -OCHF2, -OCH2F, Cl, F, -OCH3, OH, -OCF3, CH3, -CH(CH3)2, CF3, -CH2CN, CH2C(CH3)2(OH), and -C(CH3)2-OH.

[0239] Embodiment 13 of this disclosure relates to a compound according to Embodiment 11, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] ţ

[0240] Embodiment 14 of this disclosure relates to a compound according to Embodiment 13, wherein G1 is benzyloxy, -C(=CH2)CH3, -C(O)OH, -C(O)NH2, -C(O)N(H)-cyclopropyl, cyclopropyl, -CH2- cyclopropyl, cyclopropylalkynylene, -CH2-SO2-CH3, -SO2-CH3, -(CH2)N(CH3)2, -(CH2)2-N(CH3)2, -CH2- cyclopropyl, -(CH2)2-CN, -C(O)OC(CH3)3, -C(O)CH3, -C(O)C(CH3)3, -CH2C(O)N(CH3)2, cyano, or -SO2CH3; and each G2 is independently -OCHF2, -OCH2F, Cl, F, -OCH3, OH, -OCF3, CH3, -CH(CH3)2, CF3, -CH2CN, CH2C(CH3)2(OH), and -C(CH3)2-OH.

[0241] Embodiment 15 of this disclosure relates to a compound according to any one of Embodiments 1-14, including any subembodiments thereof where applicable, wherein R5, when attached to carbon, is: [Image disponible dans le document PDF, Image available in the PDF document] : Subembodiments of Embodiment 15

[0242] Embodiment 15(a) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] •

[0243] Embodiment 15(b) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0244] Embodiment 15(c) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] *

[0245] Embodiment 15(d) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0246] Embodiment 15(d) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0247] Embodiment 15(e) of this disclosure relates to Embodiment 15, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0248] Embodiment 16 of this disclosure relates to a compound according to any one of Embodiments 1-14, including any subembodiments thereof where applicable, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] • Subembodiments of Embodiment 16

[0249] Embodiment 16(a) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] •

[0250] Embodiment 16(b) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] r

[0251] Embodiment 16(c) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0252] Embodiment 16(d) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0253] Embodiment 16(e) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0254] Embodiment 16(f) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ,

[0255] Embodiment 16(g) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] •

[0256] Embodiment 16(h) of this disclosure relates to Embodiment 16, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ,

[0257] Embodiment 17 of this disclosure relates to a compound according to any one of Embodiments 1-14, including any subembodiments thereof where applicable, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ,

[0258] Embodiment 18 of this disclosure relates to a compound according to any one of Embodiments 1-14, including any subembodiments thereof where applicable, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠ Subembodiments of Embodiment 18

[0259] Embodiment 18(a) of this disclosure relates to Embodiment 18, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] .

[0260] Embodiment 18(b) of this disclosure relates to Embodiment 18, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0261] Embodiment 18(c) of this disclosure relates to Embodiment 18, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0262] Embodiment 18(d) of this disclosure relates to Embodiment 18, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0263] Embodiment 18(e) of this disclosure relates to Embodiment 18, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0264] Embodiment 19 of this disclosure relates to a compound according to any one of Embodiments 15-18, including any subembodiments thereof where applicable, wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] each J2 is independently -O-cyclobutyl, -OCH2-phenyl, -O-cyclopropyl, -O-CH2-cyclopropyl, cyclopropylethynylene, CN, OH, cyclopropyl, F, Cl, -OCH3, -OCH2, OCF3, -OCH2CF3, -OCH2CHF2, -OCH(CH3)2, -CH2CH3, -OCH2CH3, -OCH2CH2CH3, and CH3.

[0265] Embodiment 20 of this disclosure relates to a compound according to Embodiment 19, wherein: [Image disponible dans le document PDF, Image available in the PDF document] each J2 is independently F, Cl, -OCH3, -OCH5, OCF3, -OCH2CF3, -OCH2CHF2, -OCH(CH3)2, -CH2CH3, -OCH2CH3, -OCH2CH2CH3, and CH3.

[0266] Embodiment 21 of this disclosure relates to a compound according to Embodiment 1 having any one of Formulae <semantics>IV(a)−IV(c)<annotation encoding="application / x-tex">IV(a) - IV(c)< / annotation>< / semantics>: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: <semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics> is: [Image disponible dans le document PDF, Image available in the PDF document] , <semantics>J1<annotation encoding="application / x-tex">J^1< / annotation>< / semantics> is -C(O)OH or -C(O)OCH3; each J2 is independently F, Cl, -OCH3, -OCH5, OCF3, -OCH2CF3, -OCH2CHF2, -OCH(CH3)2, -CH2CH3, -OCH2CH3, -OCH2CH2CH3, and CH3; <semantics>−L−R1<annotation encoding="application / x-tex">-L-R^1< / annotation>< / semantics> is [Image disponible dans le document PDF, Image available in the PDF document] wherein G1 is benzyloxy, -C(=CH2)CH3, -C(O)OH, -C(O)NH2, -C(O)N(H)-cyclopropyl, cyclopropyl, -CH2-cyclopropyl, cyclopropylalkynylene, -CH2-SO2-CH3, -SO2-CH3, -(CH2)N(CH3)2, [Image disponible dans le document PDF, Image available in the PDF document] each G2 is independently -OCHF2, -OCH2F, Cl, F, -OCH3, OH, -OCF3, CH3, -CH(CH3)2, CF3, <semantics>CN<annotation encoding="application / x-tex">CN< / annotation>< / semantics>, <semantics>−CH2CN<annotation encoding="application / x-tex">-CH_2CN< / annotation>< / semantics>, <semantics>CH2C(CH3)2(OH)<annotation encoding="application / x-tex">CH_2C(CH_3)_2(OH)< / annotation>< / semantics>, and <semantics>−C(CH3)2−OH<annotation encoding="application / x-tex">-C(CH_3)_2-OH< / annotation>< / semantics>. Subembodiments of Embodiment 21

[0267] Embodiment 21(a1) of this disclosure relates to Embodiment 21 having Formula IV(a) or Formula IV(c).

[0268] Embodiment 21(a) of this disclosure relates to Embodiment 21 having Formula IV(a).

[0269] Embodiment 21(b) of this disclosure relates to Embodiment 21 having Formula IV(b).

[0270] Embodiment 21(c) of this disclosure relates to Embodiment 21 having Formula IV(c).

[0271] Embodiment 21(d) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0272] Embodiment 21(e) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0273] Embodiment 21(f) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0274] Embodiment 21(g) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0275] Embodiment 21(g) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0276] Embodiment 21(h) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0277] Embodiment 21(i) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0278] Embodiment 21(j) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0279] Embodiment 21(k) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0280] Embodiment 21(1) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), wherein R5 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0281] Embodiment 21(m) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0282] Embodiment 21(n) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0283] Embodiment 21(o) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0284] Embodiment 21(p) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0285] Embodiment 21(q) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0286] Embodiment 21(r) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] ٠

[0287] Embodiment 21(s) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] *

[0288] Embodiment 21(t) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] •

[0289] Embodiment 21(u) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0290] Embodiment 21(v) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0291] Embodiment 21(w) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0292] Embodiment 21(x) of this disclosure relates to any one of Embodiments 21, 21(a1), 21(a), 21(b), or 21(c), 21(d), 21(e), 21(f), 21(g), 21(h), 21(i), 21(j), 21(k), or 21(l), wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document]

[0293] Embodiment 22 relates to a compound according to Embodiment 1 of this disclosure that is selected from Table 1 of this disclosure, or a pharmaceutically acceptable salt thereof.

[0294] Compounds contemplated herein are described with reference to both generic formulae and specific compounds. In addition, the compounds described herein may exist in a number of different forms or derivatives, all within the scope of the present disclosure. These include, for example, tautomers, stereoisomers, racemic mixtures, regioisomers, salts, prodrugs (e.g. carboxylic acid esters), solvated forms, and active metabolites.

[0295] It is understood that some compounds may exhibit tautomerism. In such cases, the formulae provided herein expressly depict only one of the possible tautomeric forms. It is therefore to be understood that the formulae provided herein are intended to represent any tautomeric form of the depicted compounds and are not to be limited merely to the specific tautomeric form depicted by the drawings of the formulae.

[0296] Likewise, some of the compounds according to the present disclosure may exist as stereoisomers as defined herein. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present disclosure. Unless specified to the contrary, all such stereoisomeric forms are included within the formulae provided herein.

[0297] In some embodiments, a chiral compound of the present disclosure is in a form that contains at least 80% of a single isomer (60% enantiomeric excess ("e.e.") or diastereomeric excess ("d.e.")), or at least 85% (70% e.e. or d.e.), 90% (80% e.e. or d.e.), 95% (90% e.e. or d.e.), 97.5% (95% e.e. or d.e.), or 99% (98% e.e. or d.e.). As generally understood by those skilled in the art, an optically pure compound having one chiral center is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure. In some embodiments, the compound is present in optically pure form.

[0298] For compounds in which synthesis involves addition of a single group at a double bond, particularly a carbon-carbon double bond, the addition may occur at either of the double bond-linked atoms. For such compounds, the present disclosure includes both such regioisomers.

[0299] In addition to the present formulae and compounds described herein, the disclosure also includes prodrugs (generally pharmaceutically acceptable prodrugs), active metabolic derivatives (active metabolites), and their pharmaceutically acceptable salts.

[0300] Unless specified to the contrary, specification of a compound herein includes pharmaceutically acceptable salts of such compound.

[0301] In some embodiments, compounds of the disclosure are complexed with an acid or a base, including base addition salts such as ammonium, diethylamine, ethanolamine, ethylenediamine, diethanolamine, t-butylamine, piperazine, meglumine; acid addition salts, such as acetate, acetylsalicylate, besylate, camsylate, citrate, formate, fumarate, glutarate, hydrochlorate, maleate, mesylate, nitrate, oxalate, phosphate, succinate, sulfate, tartrate, thiocyanate and tosylate; and amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histid ne, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine. In some instances, the amorphous form of the complex is facilitated by additional processing, such as by spray-drying, mechanochemical methods such as roller compaction, or microwave irradiation of the parent compound mixed with the acid or base. Such methods may also include addition of ionic and / or non-ionic polymer systems, including, but not limited to, hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and methacrylic acid copolymer (e.g. Eudragit® L100-55), that further stabilize the amorphous nature of the complex. Such amorphous complexes provide several advantages. For example, lowering of the melting temperature relative to the free base facilitates additional processing, such as hot melt extrusion, to further improve the biopharmaceutical properties of the compound. Also, the amorphous complex is readily friable, which provides improved compression for loading of the solid into capsule or tablet form.

[0302] Additionally, the formulae are intended to cover hydrated or solvated as well as unhydrated or unsolvated forms of the identified structures. For example, the indicated compounds include both hydrated and non-hydrated forms. Other examples of solvates include the structures in combination with a suitable solvent, such as isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, or ethanolamine. Ш. Formulations and Administration

[0024] Embodiment 23 of this disclosure relates to a pharmaceutical composition comprising a compound in one of Embodiments of this disclosure relates to a compound according to any one of Embodiments 1-22, including any subembodiments thereof, wherein, and a pharmaceutically acceptable carrier.

[0025] Embodiment 24 of this disclosure relates to a pharmaceutical composition of Embodiment 23, further comprising a second pharmaceutical agent.

[0026] Suitable dosage forms, in part, depend upon the use or the route of administration, for example, oral, transdermal, transmucosal, inhalant, or by injection (parenteral). Such dosage forms should allow the compound to reach target cells. Other factors are well known in the art, and include considerations such as toxicity and dosage forms that retard the compound or composition from exerting its effects. Techniques and formulations generally may be found in The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Philadelphia, PA, 2005.

[0027] Compounds of the present disclosure (i.e. any of the compounds described in Embodiments 1- 22, including any of the subembodiments thereof) can be formulated as pharmaceutically acceptable salts.

[0028] Carriers or excipients can be used to produce compositions. The carriers or excipients can be chosen to facilitate administration of the compound. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. Examples of physiologically compatible solvents include sterile solutions of water for injection (WFI), saline solution, and dextrose.

[0029] The compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, transmucosal, rectal, transdermal, or inhalant. In some embodiments, the compounds can be administered by oral administration. For oral administration, for example, the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.

[0030] For inhalants, compounds of the disclosure may be formulated as dry powder or a suitable solution, suspension, or aerosol. Powders and solutions may be formulated with suitable additives known in the art. For example, powders may include a suitable powder base such as lactose or starch, and solutions may comprise propylene glycol, sterile water, ethanol, sodium chloride and other additives, such as acid, alkali and buffer salts. Such solutions or suspensions may be administered by inhaling via spray, pump, atomizer, or nebulizer, and the like. The compounds of the disclosure may also be used in combination with other inhaled therapies, for example corticosteroids such as fluticasone propionate, beclomethasone dipropionate, triamcinolone acetonide, budesonide, and mometasone furoate; beta agonists such as albuterol, salmeterol, and formoterol; anticholinergic agents such as ipratropium bromide or tiotropium; vasodilators such as treprostinal and iloprost; enzymes such as DNAase; therapeutic proteins; immunoglobulin antibodies; an oligonucleotide, such as single or double stranded DNA or RNA, siRNA; antibiotics such as tobramycin; muscarinic receptor antagonists; leukotriene antagonists; cytokine antagonists; protease inhibitors; cromolyn sodium; nedocril sodium; and sodium cromoglycate.

[0310] Pharmaceutical preparations for oral use can be obtained, for example, by combining the active compounds with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose (CMC), and / or polyvinylpyrrolidone (PVP: povidone). If desired, disintegrating agents may be added, such as the cross- linked polyvinylpyrrolidone, agar, or alginic acid, or a salt thereof such as sodium alginate.

[0311] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain, for example, gum arabic, talc, poly- vinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0312] Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin ("gelcaps"), as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In sof: capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs). In addition, stabilizers may be added.

[0313] Alternatively, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and / or subcutaneous. For injection, the compounds of the disclosure are formulated in sterile liquid solutions, such as in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.

[0314] Administration can also be by transmucosal, topical, transdermal, or inhalant means. For transmucosal, topical or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays or suppositories (rectal or vaginal).

[0315] The topical compositions of this disclosure are formulated as oils, creams, lotions, ointments, and the like by choice of appropriate carriers known in the art. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than <semantics>C12<annotation encoding="application / x-tex">C_{12}< / annotation>< / semantics>). In another embodiment, the carriers are those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Creams for topical application are formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount solvent (e.g. an oil), is admixed. Additionally, administration by transdermal means may comprise a transdermal patch or dressing such as a bandage impregnated with an active ingredient and optionally one or more carriers or diluents known in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

[0316] The amounts of various compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, the biological half-life of the compound, the age, size, and weight of the subject, and the indication being treated. The importance of these and other factors are well known to those of ordinary skill in the art. Generally, a dose will be between about 0.01 and 50 mg / kg, or 0.1 and 20 mg / kg of the subject being treated. Multiple doses may be used.

[0317] The compounds of the disclosure may also be used in combination with other therapies for treating the same disease. Such combination use includes administration of the compounds and one or more other therapeutics at different times, or co-administration of the compound and one or more other therapies. In some embodiments, dosage may be modified for one or more of the compounds of the disclosure or other therapeutics used in combination, e.g., reduction in the amount dosed relative to a compound or therapy used alone, by methods well known to those of ordinary skill in the art.

[0318] It is understood that use in combination includes use with other therapies, drugs, medical procedures etc., where the other therapy or procedure may be administered at different times (e.g. within a short time, such as within hours (e.g. 1, 2, 3, 4-24 hours), or within a longer time (e.g. 1-2 days, 2-4 days, 4-7 days, 1-4 weeks)) than a compound of the present disclosure, or at the same time as a compound of the disclosure. Use in combination also includes use with a therapy or medical procedure that is administered once or infrequently, such as surgery, along with a compound of the disclosure administered within a short time or longer time before or after the other therapy or procedure. In some embodiments, the present disclosure provides for delivery of compounds of the disclosure and one or more other drug therapeutics delivered by a different route of administration or by the same route of administration. The use in combination for any route of administration includes delivery of compounds of the disclosure and one or more other drug therapeutics delivered by the same route of administration together in any formulation, including formulations where the two compounds are chemically linked in such a way that they maintain their therapeutic activity when administered. In one aspect, the other drug therapy may be co-administered with one or more compounds of the disclosure. Use in combination by co-administration includes administration of co-formulations or formulations of chemically joined compounds, or administration of two or more compounds in separate formulations within a short time of each other (e.g. within an hour, 2 hours, 3 hours, up to 24 hours), administered by the same or different routes. Co-administration of separate formulations includes co-administration by delivery via one device, for example the same inhalant device, the same syringe, etc., or administration from separate devices within a short time of each other. Co-formulations of compounds of the disclosure and one or more additional drug therapies delivered by the same route includes preparation of the materials together such that they can be administered by one device, including the separate compounds combined in one formulation, or compounds that are modified such that they are chemically joined, yet still maintain their biological activity. Such chemically joined compounds may have a linkage that is substantially maintained in vivo, or the linkage may break down in vivo, separating the two active components. IV. Methods of Use

[0319] The methods and compounds will typically be used in therapy for human subjects. However, they may also be used to treat similar or identical indications in other animal subjects.

[0320] In certain embodiments, the patient is 60 years or older and relapsed after a first line cancer therapy. In certain embodiments, the patient is 18 years or older and is relapsed or refractory after a second line cancer therapy. In certain embodiments, the patient is 60 years or older and is primary refractory to a first line cancer therapy. In certain embodiments, the patient is 70 years or older and is previously untreated. In certain embodiments, the patient is 70 years or older and is ineligible and / or unlikely to benefit from cancer therapy.

[0321] In certain embodiments, the therapeutically effective amount used in the methods provided herein is at least 10 mg per day. In certain embodiments, the therapeutically effective amount is 10, 50, 90, 100, 135, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2200, 2500 mg per day. In other embodiments, the therapeutically effect ve amount is 10, 50, 90, 100, 135, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2200, 2500, 3000, 3500, 4000, 4500, 5000 mg per day or more. In certain embodiments, the compound is administered continuously.

[0322] In certain embodiments, provided herein is a method for treating a diseases or condition mediated by EP300 or CBP by administering to a mammal having a disease or condition at least 10, 50, 90, 100, 135, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2200, 2500, 3000, 3500, 4000, 4500, 5000 mg per day of any of the compounds described in a compound in one of Embodiments 1-22, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, and wherein the compound is administered on an empty stomach.

[0323] Embodiment 25 of this disclosure relates to a method for treating a subject with a disease or condition mediated by EP300 or CBP, said method comprising administering to the subject an effective amount of a compound in one of Embodiments 1-22, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, or a pharmaceutical composition in one of Embodiments 23-24.

[0324] Embodiment 26 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 25, wherein the disease or condition is a cancer that harbors inactivating mutations in CBP or EP300, or a cancer where there is activation of EP300 or CBP.

[0325] Embodiment 27 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 25, wherein the disease or condition is a cancer that expresses the androgen receptor.

[0326] Embodiment 28 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 25, wherein the disease or condition is a neoplastic disorder, a cancer, an inflammatory disorder, an age-related disease, a cognitive disorder and or a neurodegenerative disease.

[0327] Embodiment 29 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 25, wherein the disease or condition is acral lentiginous melanoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, bladder cancer, adenocarcinoma, adult T-cell leukemia / lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, bone cancer, Burkitt's lymphoma, cutaneous T-cell lymphoma, colorectal cancer, diffuse large B-cell lymphoma, enteropathy- associated T-cell lymphoma, follicular lymphoma, glioblastoma multiforme, glioma, gastric cancer, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant peripheral nerve sheath tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, breast cancer, medulloblastoma, melanoma, merkel cell cancer, mesothelioma, multiple myeloma, neuroblastoma, neurofibroma, nodular melanoma, osteosarcoma, ovarian cancer, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, prostate cancer, pancreatic cancer, skin cancer, T-cell lymphoma, uveal melanoma, Alzheimer's disease, Parkinson's disease, or colorectal cancer.

[0328] Embodiment 29(a) of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is acute myeloid leukemia.

[0329] Embodiment 29(b) of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is multible myeloma.

[0330] Embodiment 29(c) of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is prostate cancer.

[0331] Embodiment 29(d) of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is prostate cancer.

[0332] Embodiment 30 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is small-cell lung cancer, non- small cell lung cancer, bladder cancer, non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, diffuse large B-cell lymphoma, breast cancer or prostate cancer.

[0333] Embodiment 31 of this disclosure relates to the method for treating a subject with a disease or condition according to Embodiment 29, wherein the disease or condition is Alzheimer's disease or Parkinson's disease. V. Combination Therapy

[0334] EP300 and CBP modulators may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of cancer. In one embodiment, the composition includes any one or more compound(s) as described herein along with one or more compounds that are therapeutically effective for the same disease indication, wherein the compounds have a synergistic effect on the disease indication. In one embodiment, the composition includes any one or more compound(s) as described herein effective in treating a cancer and one or more other compounds that are effective in treating the same cancer, further wherein the compounds are synergistically effective in treating the cancer.

[0335] In another embodiment, the present disclosure provides methods for treating a disease or condition mediated by EP300 or CBP by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other suitable therapies for treating the disease.

[0336] Embodiment 32 of this disclosure relates to the method according to any one of Embodiments 25-31, or any sub-embodiments thereof, further comprising administering one or more additional therar eutic agents.

[0337] Embodiment 33 of this disclosure relates to the method according Embodiment 32, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from the group consisting of azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an immunotherapy agent (including PD-1 or PD-L1 inhibitors) selected from alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, nivolumab, panitumumab, pembrolizumab, pertuzumab, rituximab, tositumomab, trastuzumab, and 90 Y ibritumomab tiuxetan; v) a hormone or hormone antagonist selected from the group consisting of enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9- aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS- 354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), vemurafenib, dabrafenib, trametinib, cobimetinib selumetinib and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-α and interleukin-2; xiv) an IDO inhibitor; and xv) a chemotherapeutic agent selected from 3- AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389), ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, a mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor or an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a Mek inhibitor; xvii) a tyrosine kinase inhibitor; xviii) a c-Kit mutant inhibitor, xix) an EGFR inhibitor, a PD-1 inhibitor, or xx) an epigenetic modulator.

[0338] Embodiment 33(a) of this disclosure relates to the method according Embodiment 32, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent selected from adoze esin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from the group consisting of azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an immunotherapy agent selected from a PD-1 or PD-L1 inhibitor; v) a hormone or hormone antagonist selected from the group consisting of enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN- 38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9-aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01 (7- hydroxystaurosporine), vemurafenib, dabrafenib, trametinib, cobimetinib selumetinib and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-α and interleukin-2; xiv) an IDO inhibitor; and xv) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389), ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, a mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor or an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a Mek inhibitor; xvii) a tyrosine kinase inhibitor; xviii) a c-Kit mutant inhibitor, xix) an EGFR inhibitor, a PD-1 inhibitor, or xx) an epigenetic modulator.

[0339] Embodiment 34 of this disclosure relates to the method according Embodiment 33, wherein the one or more additional therapeutic agents is an epigenetic modulator selected from the group consisting of: (a) a DNA methyltransferase; (b) a histone or protein methyltransferase; (c) a histone demethylase; (d) a histone deacetylase inhibitor; (f) other chromatin remodelers; and (g) a BRD4 inhibitor.

[0340] Embodiment 35 of this disclosure relates to the method according to Embodiment 34, wherein the epigenetic modulator is a histone deacetylase inhibitor selected from the group consisting of vorinostat, romidepsin, chidamide, panobinostat, belinostat, valproic acid, mocetinostat, abexinostat, entinostat, resminostat, givinostat, and quisinostat.

[0341] Embodiment 36 of this disclosure relates to the method according to Embodiment 34, wherein the epigenetic modulator is a BRD4 inhibitor.

[0342] Embodiment 37 of this disclosure relates to the method according to Embodiment 33, wherein the one or more additional therapeutic agents is a PD-1 inhibitor, quizartinib, enzalutamide, abiraterone, or a BRD4 inhibitor.

[0343] Embodiment 38 of this disclosure relates to the method according to Embodiment 33, wherein the one or more additional therapeutic agent is enzalutamide and the disease is prostate cancer including, but not limited to, castrate resistant prostate cancer.

[0344] Embodiment 39 of this disclosure relates to the method according to Embodiment 33, wherein the one or more additional therapeutic agent is abiraterone and the disease is prostate cancer including, but not limited to, castrate resistant prostate cancer.

[0345] Bromodomains (e.g., BET proteins, such as BRD2, BRD3, BRD4, and / or BRDT), and e.g., diseases related to abnormal expression of bromodomains, include cell proliferative disorders, cancers, chronic autoimmune, and inflammatory conditions, among others. Non-limiting examples of BET inhibitors include PLX1107, GSK1210151A and GSK525762.

[0346] The histone deacetylase inhibitors (HDAC inhibitors) are cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and / or apoptosis. HDAC inhibitors exert their anti-tumor effects via the induction of expression changes of oncogenes or tumour suppressor, through modulating that the acetylation / deactylation of histones and / or non-histone proteins such as transcription factors. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regulation of gene transcription. Non-limiting examples of HDAC inhibitors include vorinostat, romidepsin, chidamide, panobinostat, belinostat, valproic acid, mocetinostat, abexinostat, entinostat, resminostat, givinostat, and quisinostat. HDAC inhibitors have been used extensively in psychiatry and neurology as mood stabilzers and anti-epileptics. One example of this is valproic acid, marketed as a drug under the trade names Depakene, Depakote, and Divalproex. HDAC inhibitors are also being used as a mitigator for neurodegenerative diseases such as Alzheimer's disease and Huntington's disease.

[0347] In another embodiment, the present disclosure provides a method of treating a cancer in a subject in need thereof by administering to the subject an effective amount of a composition including any one or more compound(s) as described herein in combination with one or more other therapies or medical procedures effective in treating the cancer. Other therapies or medical procedures include suitable anticancer therapy (e.g. drug therapy, vaccine therapy, gene therapy, photodynamic therapy) or medical procedure (e.g. surgery, radiation treatment, hyperthermia heating, bone marrow or stem cell transplant). In one embodiment, the one or more suitable anticancer therapies or medical procedures is selected from treatment with a chemotherapeutic agent (e.g. chemotherapeutic drug), radiation treatment (e.g. x-ray, .gamma.-ray, or electron, proton, neutron, or .alpha. particle beam), hyperthermia heating (e.g. microwave, ultrasound, radiofrequency ablation), Vaccine therapy (e.g. AFP gene hepatocellular carcinoma vaccine, AFP adenoviral vector vaccine, AG-858, allogeneic GM-CSF-secretion breast cancer vaccine, dendritic cell peptide vaccines), gene therapy (e.g. Ad5CMV-p53 vector, adenovector encoding MDA7, adenovirus 5-tumor necrosis factor alpha), photodynamic therapy (e.g. aminolevulinic acid, motexatin lutetium), surgery, or bone marrow and stem cell transplantation. VI. Kits

[0348] In another aspect, the present disclosure provides kits that include one or more compounds as described in any one of a compound in one of Embodiments 1-22, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, or a pharmaceutical composition in one of Embodiments 23-24. In some embodiments, the compound or composition is packaged, e.g., in a vial, bottle, flask, which may be further packaged, e.g., within a box, envelope, or bag. The compound or composition may be approved by the U.S. Food and Drug Administration or similar regulatory agency for administration to a mammal, e.g., a human. The compound or composition may be approved for administration to a mammal, e.g., a human, for an EP300 or CBP mediated disease or condition. The kits described herein may include written instructions for use and / or other indication that the compound or composition is suitable or approved for administration to a mammal, e.g., a human, for an EP300 or CBP mediated disease or condition. The compound or composition may be packaged in unit dose or single dose form, e.g., single dose pills, capsules, or the like. VII. Binding Assays

[0349] The methods of the present disclosure can involve assays that are able to detect the binding of compounds to a target molecule. Such binding is at a statistically significant level, with a confidence level of at least 90%, or at least 95, 97, 98, 99% or greater confidence level that the assay signal represents binding to the target molecule, i.e., is distinguished from background. In some embodiments, controls are used to distinguish target binding from non-specific binding. A large variety of assays indicative of binding are known for different target types and can be used for this disclosure.

[0350] Binding compounds can be characterized by their effect on the activity of the target molecule. Thus, a "low activity" compound has an inhibitory concentration (IC50) or effective concentration (EC50) of greater than 1 μM under standard conditions. By "very low activity" is meant an IC50 or EC50 of above 100 μM under standard conditions. By "extremely low activity" is meant an IC50 or EC50 of above 1 mM under standard conditions. By "moderate activity" is meant an IC50 or EC50 of 200 nM to 1 μM under standard conditions. By "moderately high activity" is meant an IC50 or EC50 of 1 nM to 200 nM. By "high activity" is meant an IC50 or EC50 of below 1 nM under standard conditions. The IC50 or EC50 is defined as the concentration of compound at which 50% of the activity of the target molecule (e.g. enzyme or other protein) activity being measured is lost or gained relative to the range of activity observed when no compound is present. Activity can be measured using methods known to those of ordinary skill in the art, e.g., by measuring any detectable product or signal produced by occurrence of an enzymatic reaction, or other activity by a protein being measured.

[0351] By "background signal" in reference to a binding assay is meant the signal that is recorded under standard conditions for the particular assay in the absence of a test compound, molecular scaffold, or ligand that binds to the target molecule. Persons of ordinary skill in the art will realize that accepted methods exist and are widely available for determining background signal.

[0352] By "standard deviation" is meant the square root of the variance. The variance is a measure of how spread out a distribution is. It is computed as the average squared deviation of each number from its mean. For example, for the numbers 1, 2, and 3, the mean is 2 and the variance is: [Image disponible dans le document PDF, Image available in the PDF document] Surface Plasmon Resonance

[0031] Binding parameters can be measured using surface plasmon resonance, for example, with a BIAcore® chip (Biacore, Japan) coated with immobilized binding components. Surface plasmon resonance is used to characterize the microscopic association and dissociation constants of reaction between an sFv or other ligand directed against target molecules. Such methods are generally described in the following references. Vely F. et al., (2000) BIAcore® analysis to test phosphopeptide-SH2 domain interactions, Methods in Molecular Biology. 121:313-21; Liparoto et al., (1999) Biosensor analysis of the interleukin-2 receptor complex, Journal of Molecular Recognition. 12:316-21; Lipschultz et al., (2000) Experimental design for analysis of complex kinetics using surface plasmon resonance, Methods. 20(3):310-8; Malmqvist., (1999) BIACORE: an affinity biosensor system for characterization of biomolecular interactions, Biochemical Society Transactions 27:335-40; Alfthan, (1998) Surface plasmon resonance biosensors as a tool in antibody engineering, Biosensors & Bioelectronics. 13:653-63; Fivash et al., (1998) BIAcore for macromolecular interaction, Current Opinion in Biotechnology. 9:97- 101; Price et al.; (1998) Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biology 19 Suppl 1:1-20; Malmqvist et al, (1997) Biomolecular interaction analysis: affinity biosensor technologies for functional analysis of proteins, Current Opinion in Chemical Biology. 1:378-83; O'Shannessy et al., (1996) Interpretation of deviations from pseudo-first-order kinetic behavior in the characterization of ligand binding by biosensor technology, Analytical Biochemistry. 236:275-83; Malmborg et al., (1995) BIAcore as a tool in antibody engineering, Journal of Immunological Methods. 183:7-13; Van Regenmortel, (1994) Use of biosensors to characterize recombinant proteins, Developments in Biological Standardization. 83:143-51; and O'Shannessy, (1994) Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: a critique of the surface plasmon resonance literature, Current Opinions in Biotechnology. 5:65-71.

[0032] BIAcore® uses the optical properties of surface plasmon resonance (SPR) to detect alterations in protein concentration bound to a dextran matrix lying on the surface of a gold / glass sensor chip interface, a dextran biosensor matrix. In brief, proteins are covalently bound to the dextran matrix at a known concentration and a ligand for the protein is injected through the dextran matrix. Near infrared light, directed onto the opposite side of the sensor chip surface is reflected and also induces an evanescent wave in the gold film, which in turn, causes an intensity dip in the reflected light at a particular angle known as the resonance angle. If the refractive index of the sensor chip surface is altered (e.g. by ligand binding to the bound protein) a shift occurs in the resonance angle. This angle shift can be measured and is expressed as resonance units (RUs) such that 1000 RUs is equivalent to a change in surface protein concentration of 1 ng / mm2. These changes are displayed with respect to time along the y- axis of a sensorgram, which depicts the association and dissociation of any biological reaction. High Throughput Screening (HTS) Assays

[0355] HTS typically uses automated assays to search through large numbers of compounds for a desired activity. Typically HTS assays are used to find new drugs by screening for chemicals that act on a particular enzyme or molecule. For example, if a chemical inactivates an enzyme it might prove to be effective in preventing a process in a cell which causes a disease. High throughput methods enable researchers to assay thousands of different chemicals against each target molecule very quickly using robotic handling systems and automated analysis of results.

[0356] As used herein, "high throughput screening" or "HTS" refers to the rapid in vitro screening of large numbers of compounds (libraries); generally tens to hundreds of thousands of compounds, using robotic screening assays. Ultra-high-throughput Screening (uHTS) generally refers to the high- throughput screening accelerated to greater than 100,000 tests per day.

[0357] To achieve high-throughput screening, it is advantageous to house samples on a multicontainer carrier or platform. A multicontainer carrier facilitates measuring reactions of a plurality of candidate compounds simultaneously. Multi-well microplates may be used as the carrier. Such multi-well microplates, and methods for their use in numerous assays, are both known in the art and commercially available.

[0358] Screening assays may include controls for purposes of calibration and confirmation of proper manipulation of the components of the assay. Blank wells that contain all of the reactants but no member of the chemical library are usually included. As another example, a known inhibitor (or activator) of an enzyme for which modulators are sought, can be incubated with one sample of the assay, and the resulting decrease (or increase) in the enzyme activity used as a comparator or control. It will be appreciated that modulators can also be combined with the enzyme activators or inhibitors to find modu ators which inhibit the enzyme activation or repression that is otherwise caused by the presence of the known the enzyme modulator. Measuring Enzymatic and Binding Reactions During Screening Assays

[0359] Techniques for measuring the progression of enzymatic and binding reactions, e.g., in multicontainer carriers, are known in the art and include, but are not limited to, the following.

[0360] Spectrophotometric and spectrofluorometric assays are well known in the art. Examples of such assays include the use of colorimetric assays for the detection of peroxides, as described in Gordon, A. J. and Ford, R. A., (1972) The Chemist's Companion: A Handbook Of Practical Data, Techniques, And References, John Wiley and Sons, N.Y., Page 437.

[0361] Fluorescence spectrometry may be used to monitor the generation of reaction products. Fluorescence methodology is generally more sensitive than the absorption methodology. The use of fluorescent probes is well known to those skilled in the art. For reviews, see Bashford et al., (1987) Spectrophotometry and Spectrofluorometry: A Practical Approach, pp. 91-114, IRL Press Ltd.; and Bell, (1981) Spectroscopy In Biochemistry, Vol. I, pp. 155-194, CRC Press.

[0362] In spectrofluorometric methods, enzymes are exposed to substrates that change their intrinsic fluorescence when processed by the target enzyme. Typically, the substrate is nonfluorescent and is converted to a fluorophore through one or more reactions. As a non-limiting example, SMase activity can be detected using the Amplex® Red reagent (Molecular Probes, Eugene, OR). In order to measure sphingomyelinase activity using Amplex® Red, the following reactions occur. First, SMase hydrolyzes sphingomyelin to yield ceramide and phosphorylcholine. Second, alkaline phosphatase hydrolyzes phosphorylcholine to yield choline. Third, choline is oxidized by choline oxidase to betaine. Finally, <semantics>H2O2<annotation encoding="application / x-tex">H_2O_2< / annotation>< / semantics>, in the presence of horseradish peroxidase, reacts with Amplex® Red to produce the fluorescent product, Resorufin, and the signal therefrom is detected using spectrofluorometry.

[0363] Fluorescence polarization (FP) is based on a decrease in the speed of molecular rotation of a fluorophore that occurs upon binding to a larger molecule, such as a receptor protein, allowing for polarized fluorescent emission by the bound ligand. FP is empirically determined by measuring the vertical and horizontal components of fluorophore emission following excitation with plane polarized light. Polarized emission is increased when the molecular rotation of a fluorophore is reduced. A fluorophore produces a larger polarized signal when it is bound to a larger molecule (i.e. a receptor), slowing molecular rotation of the fluorophore. The magnitude of the polarized signal relates quantitatively to the extent of fluorescent ligand binding. Accordingly, polarization of the "bound" signal depends on maintenance of high affinity binding.

[0364] FP is a homogeneous technology and reactions are very rapid, taking seconds to minutes to reach equilibrium. The reagents are stable, and large batches may be prepared, resulting in high reproducibility. Because of these properties, FP has proven to be highly automatable, often performed with ε single incubation with a single, premixed, tracer-receptor reagent. For a review, see Owicki et al., (1997), Application of Fluorescence Polarization Assays in High-Throughput Screening, Genetic Engineering News, 17:27.

[0365] FP is particularly desirable since its readout is independent of the emission intensity (Checovich, W. J., et al., (1995) Nature 375:254-256; Dandliker, W. B., et al., (1981) Methods in Enzymology 74:3-28) and is thus insensitive to the presence of colored compounds that quench fluorescence emission. FP and FRET (see below) are well-suited for identifying compounds that block interactions between sphingolipid receptors and their ligands. See, for example, Parker et al., (2000) Development of high throughput screening assays using fluorescence polarization: nuclear receptor- ligand-binding and kinase / phosphatase assays, J Biomol Screen 5:77-88.

[0366] Fluorophores derived from sphingolipids that may be used in FP assays are commercially available. For example, Molecular Probes (Eugene, OR) currently sells sphingomyelin and one ceramide flurophores. These are, respectively, N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3- pentanoyl)sphingosyl phosphocholine (BODIPY® FL C5-sphingomyelin); N-(4,4-difluoro-5,7-dimethyl- 4-bora-3a,4a-diaza-s-indacene- 3-dodecanoyl)sphingosyl phosphocholine (BODIPY® FL C12- sphingomyelin); and N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3- pentanoyl)sphingosine (BODIPY® FL C5-ceramide). U.S. Patent No. 4,150,949, (Immunoassay for gentamicin), discloses fluorescein-labelled gentamicins, including fluoresceinthiocarbanyl gentamicin. Additional fluorophores may be prepared using methods well known to the skilled artisan.

[0367] Exemplary normal-and-polarized fluorescence readers include the POLARION® fluorescence polarization system (Tecan AG, Hombrechtikon, Switzerland). General multiwell plate readers for other assays are available, such as the VERSAMAX® reader and the SPECTRAMAX® multiwell plate spectrophotometer (both from Molecular Devices).

[0368] Fluorescence resonance energy transfer (FRET) is another useful assay for detecting interaction and has been described. See, e.g., Heim et al., (1996) Curr. Biol. 6:178-182; Mitra et al., (1996) Gene 173:13-17; and Selvin et al., (1995) Meth. Enzymol. 246:300-345. FRET detects the transfer of energy between two fluorescent substances in close proximity, having known excitation and emission wavelengths. As an example, a protein can be expressed as a fusion protein with green fluorescent protein (GFP). When two fluorescent proteins are in proximity, such as when a protein specifically interacts with a target molecule, the resonance energy can be transferred from one excited molecule to the other. As a result, the emission spectrum of the sample shifts, which can be measured by a fluorometer, such as a fMAX multiwell fluorometer (Molecular Devices, Sunnyvale Calif.).

[0369] Scintillation proximity assay (SPA) is a particularly useful assay for detecting an interaction with the target molecule. SPA is widely used in the pharmaceutical industry and has been described (Hanselman et al., (1997) J. Lipid Res. 38:2365-2373; Kahl et al., (1996) Anal. Biochem. 243:282-283; Undenfriend et al., (1987) Anal. Biochem. 161:494-500). See also U.S. Patent Nos. 4,626,513 and 4,568,649, and European Patent No. 0,154,734. One commercially available system uses FLASHPLATE® scintillant-coated plates (NEN Life Science Products, Boston, MA).

[0370] The target molecule can be bound to the scintillator plates by a variety of well-known means. Scinti lant plates are available that are derivatized to bind to fusion proteins such as GST, His6 or Flag fusion proteins. Where the target molecule is a protein complex or a multimer, one protein or subunit can be attached to the plate first, then the other components of the complex added later under binding conditions, resulting in a bound complex.

[0371] In a typical SPA assay, the gene products in the expression pool will have been radiolabeled and added to the wells, and allowed to interact with the solid phase, which is the immobilized target molecule and scintillant coating in the wells. The assay can be measured immediately or allowed to reach equilibrium. Either way, when a radiolabel becomes sufficiently close to the scintillant coating, it produces a signal detectable by a device such as a TOPCOUNT NXT® microplate scintillation counter (Packard BioScience Co., Meriden Conn.). If a radiolabeled expression product binds to the target molecule, the radiolabel remains in proximity to the scintillant long enough to produce a detectable signal.

[0372] In contrast, the labeled proteins that do not bind to the target molecule, or bind only briefly, will not remain near the scintillant long enough to produce a signal above background. Any time spent near the scintillant caused by random Brownian motion will also not result in a significant amount of signal. Likewise, residual unincorporated radiolabel used during the expression step may be present, but will not generate significant signal because it will be in solution rather than interacting with the target molecule. These non-binding interactions will therefore cause a certain level of background signal that can be mathematically removed. If too many signals are obtained, salt or other modifiers can be added directly to the assay plates until the desired specificity is obtained (Nichols et al., (1998) Anal. Biochem. 257:112-119). General Synthesis

[0373] The compounds may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers.

[0374] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0375] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and depro ecting particular functional groups are well known in the art. For example, numerous protecting groups are described in Wuts, P. G. M., Greene, T. W., & Greene, T. W. (2006). Greene's protective groups in organic synthesis. Hoboken, N.J., Wiley-Interscience, and references cited therein.

[0376] The compounds of this disclosure may contain one or more asymmetric or chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, supercritical fluid chromathography, chiral seed crystals, chiral resolving agents, and the like.

[0377] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).

[0378] It will also be appreciated that in each of the schemes, the addition of any substituent may result in the production of a number of isomeric products (including, but not limited to, enantiomers or one or more diastereomers) any or all of which may be isolated and purified using conventional techniques. When enantiomerically pure or enriched compounds are desired, chiral chromatography and / or enantiomerically pure or enriched starting materials may be employed as conventionally used in the art or as described in the Examples.

[0379] Compounds of the present disclosure may be synthesized in accordance with the general reaction schemes and / or examples described below. The general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in corresponding products. The structure of the desired product will generally make apparent to a person of skill in the art the required starting materials.

[0380] Schemes 1 and 2 provide exemplary synthetic routes for the synthesis of compounds provided herein (e.g., compounds of Formula I). The compounds of Formula I, or other formulas or compounds disclosed herein, are typically prepared by first providing the core Formula X(a) or X(d) and then attaching the desired substituents using suitable conditions (e.g., coupling).

[0381] In some embodiments, synthesis of a compound of Formula I proceeds according to Scheme 1. Scheme 1 [Image disponible dans le document PDF, Image available in the PDF document]

[0382] In Scheme 1, A1, A2, L, R1, R4, R5, X1, X2, and X3 are as defined in Formula I. In Scheme 1, a compound of Formula X(a) is converted into a compound of Formula X(b) or of Formula X(c). The compound of Formula X(b) or Formula X(c), respectively, may then be converted into a compound of Formula I.

[0383] In Scheme 1, Each of <semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>, <semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>, <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics>, and <semantics>Z4<annotation encoding="application / x-tex">Z^4< / annotation>< / semantics> is independently a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), a suitable coupling partner, e.g., a halide, a boronic acid, a boronate or hydrogen (e.g., of a terminal alkyne), or a suitable electrophile, e.g., an aldehyde or ketone.

[0384] In Scheme 1, R51 is R5a, hydrogen or a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), or a suitable coupling partner, e.g., a halide, a boronic acid, a boronate. R5a is R5 or a suitable precursor, for example, where R5 comprises a carboxylic acid, R5a may comprise an ester. Where R5 comprises a carboxylic acid, conversion of Formula X(b) to Formula I, or conversion of Formula X(a) to Formula X(c), may comprise the step of hydrolyzing an ester. R18 is -L-R1, hydrogen or a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), a suitable coupling partner, e.g., a halide, a boronic acid, a boronate, or a suitable electrophile, e.g., an aldehyde or ketone. R41 is R4. Each of <semantics>A11<annotation encoding="application / x-tex">A^{11}< / annotation>< / semantics>, <semantics>A12<annotation encoding="application / x-tex">A^{12}< / annotation>< / semantics>, and <semantics>A13<annotation encoding="application / x-tex">A^{13}< / annotation>< / semantics> is <semantics>A1<annotation encoding="application / x-tex">A^{1}< / annotation>< / semantics>. Each of <semantics>A21<annotation encoding="application / x-tex">A^{21}< / annotation>< / semantics>, <semantics>A22<annotation encoding="application / x-tex">A^{22}< / annotation>< / semantics>, and <semantics>A23<annotation encoding="application / x-tex">A^{23}< / annotation>< / semantics> is either <semantics>A2<annotation encoding="application / x-tex">A^{2}< / annotation>< / semantics> or a suitable moiety for appending <semantics>A2<annotation encoding="application / x-tex">A^{2}< / annotation>< / semantics>, e.g., a suitable coupling partner such as a halide, a boronic acid, a boronate or hydrogen.

[0385] A person of skill in the art will appreciate that any of a compound of Formula <semantics>X(a)<annotation encoding="application / x-tex">X(a)< / annotation>< / semantics>, <semantics>X(b)<annotation encoding="application / x-tex">X(b)< / annotation>< / semantics>, or X(c) may be available from a commercial supplier for a particular embodiment. Alternative synthesis of a compound of Formula X(a), X(b), or X(c) may be as described herein or as known to those of skill in the art.

[0386] In some embodiments, synthesis of a compound of Formula I proceeds according to Scheme 2. Scheme 2 [Image disponible dans le document PDF, Image available in the PDF document] 2 2

[0387] In Scheme 2, A1, A2, L, R1, R4, R5, X1, X2, and X3 are as defined in Formula I. In Scheme 1, a compound of Formula X(d) is converted into a compound of Formula X(e) or of Formula X(f). The compound of Formula X(e) or Formula X(f), respectively, may then be converted into a compound of Formula I.

[0388] In Scheme 2, Each of <semantics>Z5<annotation encoding="application / x-tex">Z^5< / annotation>< / semantics>, <semantics>Z6<annotation encoding="application / x-tex">Z^6< / annotation>< / semantics>, <semantics>Z7<annotation encoding="application / x-tex">Z^7< / annotation>< / semantics>, and <semantics>Z8<annotation encoding="application / x-tex">Z^8< / annotation>< / semantics> is independently a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), a suitable coupling partner, e.g., a halide, a boronic acid, a boronate or hydrogen (e.g., of a terminal alkyne), or a suitable electrophile, e.g., an aldehyde or ketone.

[0389] In Scheme 2, R52 is R5b, hydrogen or a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), or a suitable coupling partner, e.g., a halide, a boronic acid, a boronate. R5b is R5 or a suitable precursor, for example, where R5 comprises a carboxylic acid, R5b may comprise an ester. Where R5 comprises a carboxylic acid, conversion of Formula X(e) to Formula I, or conversion of Formula X(d) to Formula X(f), may comprise the step of hydrolyzing an ester. R19 is -L-R1, hydrogen or a suitable leaving group, e.g., a halide or hydroxide (e.g., in the presence of triphenylphosphine and a dialkylazodicarboxylate), a suitable coupling partner, e.g., a halide, a boronic acid, a boronate, or a suitable electrophile, e.g., an aldehyde, ketone, or nitrile, or an α- β-unsaturated derivative thereof, or an N-protecting group, e.g., a p-toluenesulfonyl or tert- butoxycarbonyl. R42 is either R4 or a suitable moiety for appending R4, e.g., a hydrogen. Each of A14, A15, and A16 is either A1 or a suitable moiety for appending A1, e.g., a suitable coupling partner such as a halide, a boronic acid, a boronate or hydrogen. Each of <semantics>A24<annotation encoding="application / x-tex">A^{24}< / annotation>< / semantics>, <semantics>A25<annotation encoding="application / x-tex">A^{25}< / annotation>< / semantics>, and <semantics>A26<annotation encoding="application / x-tex">A^{26}< / annotation>< / semantics> is <semantics>A2<annotation encoding="application / x-tex">A^{2}< / annotation>< / semantics>.

[0390] A person of skill in the art will appreciate that any of a compound of Formula <semantics>X(d)<annotation encoding="application / x-tex">X(d)< / annotation>< / semantics>, <semantics>X(e)<annotation encoding="application / x-tex">X(e)< / annotation>< / semantics>, or X(f) may be available from a commercial supplier for a particular embodiment. Alternative synthesis of a compound of Formula X(d), X(e), or X(f) may be as described herein or as known to those of skill in the art. Palladium coupling conditions

[0391] Where appropriate, where an (hetero)aryl carbon-(hetero)aryl carbon bond is formed, Formula X(a), X(b), X(c), X(d), X(e), or X(f) is coupled with compound 501, 502, 503, 504, 505, 506, 507, or 508 in which <semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>, <semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>, <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics>, <semantics>Z4<annotation encoding="application / x-tex">Z^4< / annotation>< / semantics>, <semantics>Z5<annotation encoding="application / x-tex">Z^5< / annotation>< / semantics>, <semantics>Z6<annotation encoding="application / x-tex">Z^6< / annotation>< / semantics>, <semantics>Z7<annotation encoding="application / x-tex">Z^7< / annotation>< / semantics>, or <semantics>Z8<annotation encoding="application / x-tex">Z^8< / annotation>< / semantics> is a suitable coupling partner, for example, a halide (e.g., bromide or iodide) or boronic acid, or ester thereof, under standard metal-catalyzed cross coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, acetonitrile, water, etc.), optionally under an inert atmosphere. The cross coupling reaction is carried out in an inert solvent, for example aqueous 1,4-dioxane or aqueous N,N-dimethylformamide, in the presence of a mild base, for example potassium acetate, potassium carbonate, sodium carbonate, or sodium bicarbonate. The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II) or dichloro 1,1'-bis(diphenylphosphino)ferrocene palladium(II), at a temperature of about 60 to 150 °C, for about 10 minutes to about 12 hours. When the reaction is substantially complete, the product is isolated by conventional means. Copper ("Buchwald") coupling conditions

[0392] Where appropriate, for example, where an (hetero)aryl carbon-nitrogen bond is formed, Formula X(a), X(b), X(c), X(d), X(e), or X(f) is coupled with compound 501, 502, 503, 504, 505, 506, 507, or 508 in which <semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>, <semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>, <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics>, <semantics>Z4<annotation encoding="application / x-tex">Z^4< / annotation>< / semantics>, <semantics>Z5<annotation encoding="application / x-tex">Z^5< / annotation>< / semantics>, <semantics>Z6<annotation encoding="application / x-tex">Z^6< / annotation>< / semantics>, <semantics>Z7<annotation encoding="application / x-tex">Z^7< / annotation>< / semantics>, or <semantics>Z8<annotation encoding="application / x-tex">Z^8< / annotation>< / semantics> is a suitable coupling partner, for example, a halide (e.g., promide or iodide), under copper-catalyzed coupling conditions (e.g., using a copper catalyst), in a suitable solvent (e.g., toluene, DMF, etc.), optionally under an inert atmosphere. The coupling reaction is carried out in an inert solvent, for example toluene or N,N-dimethylformamide, in the presence of a mild base, for example potassium carbonate, or potassium phosphate tribasic. The reaction is typically conducted in the presence of a metal catalyst, for example, copper(I) iodide, copper(I) bromide or copper(II) acetate monohydrate, with an appropriate ligand, for example trans N,N'- dimethylcyclohexane-1,2-diamine, at a temperature of about 60 to 150 °C, for about 10 minutes to about 7 days. When the reaction is substantially complete, the product is isolated by conventional means. Aryl nucleophilic displacement conditions

[0393] Where appropriate, for example, where an (hetero)aryl carbon-nitrogen bond is formed, Formula X(a), X(b), X(c), X(d), X(e), or X(f) is coupled with compound 501, 502, 503, 504, 505, 506, 507, or 508 in which <semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>, <semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>, <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics>, <semantics>Z4<annotation encoding="application / x-tex">Z^4< / annotation>< / semantics>, <semantics>Z5<annotation encoding="application / x-tex">Z^5< / annotation>< / semantics>, <semantics>Z6<annotation encoding="application / x-tex">Z^6< / annotation>< / semantics>, <semantics>Z7<annotation encoding="application / x-tex">Z^7< / annotation>< / semantics>, or <semantics>Z8<annotation encoding="application / x-tex">Z^8< / annotation>< / semantics> is a suitable leaving group, for example, a fluoride, under nucleophilic substitution-aromatic ("SNAr") conditions, in a suitable solvent (e.g., DMSO, DMF, etc.), optionally under an inert atmosphere. The reaction is carried out in an inert solvent, for example DMSO, in the presence of a mild base, for example potassium carbonate or cesium carbonate. The reaction is typically conducted at a temperature of about 60 to 150 °C, for about 1 hour to about 7 days. When the reaction is substantially complete, the product is isolated by conventional means. Alkyne coupling conditions

[0394] Where appropriate, for example, where a alkynyl carbon-nitrogen bond is formed, Formula X(a), X(b), X(c), X(d), X(e), or X(f) is coupled with compound 501, 502, 503, 504, 505, 506, 507, or 508 in which <semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>, <semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>, <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics>, <semantics>Z4<annotation encoding="application / x-tex">Z^4< / annotation>< / semantics>, <semantics>Z5<annotation encoding="application / x-tex">Z^5< / annotation>< / semantics>, <semantics>Z6<annotation encoding="application / x-tex">Z^6< / annotation>< / semantics>, <semantics>Z7<annotation encoding="application / x-tex">Z^7< / annotation>< / semantics>, or <semantics>Z8<annotation encoding="application / x-tex">Z^8< / annotation>< / semantics> is a hydrogen or trialkylsilane, under copper-catalyzed coupling conditions (e.g., using a palladium catalyst and / or a copper catalyst), in a suitable solvent (e.g., toluene, DMF, etc.), optionally under an inert atmosphere. The coupling reaction is carried out in an inert solvent, for example toluene or N,N-dimethylformamide, in the presence of a mild base, for example triethylamine. The reaction is typically conducted in the presence of a metal catalyst, for example, bis(triphenylphosphine) palladium(II) dichloride, copper(I) iodide or copper(I) bromide, optionally with an appropriate ligand, for example trans N,N'-dimethylcyclohexane-1,2-diamine, at a temperature of about 60 to 150 °C, for about 10 minutes to about 1 day. When the reaction is substantially complete, the product is isolated by conventional means. Ester hydrolysis conditions

[0395] Where appropriate, for example, where a carboxylic ester is cleaved in R1a or R5a to form a carboxylic acid in R1 or R5 respectively, Formula X(a), X(b), X(c), X(d), X(e), or X(f) is subjected to ester hydrolysis conditions. Ester hydrolysis conditions may comprise, for example, using a base such as an alkali metal alkoxide (e.g., sodium methoxide or sodium ethoxide) or an alkali metal hydroxide (e.g., sodium hydroxide or lithium hydroxide) in a suitable solvent (e.g., water, dioxane, an alcohol and / or THF), at a temperature of about 0 to 100 °C, for about 10 minutes to about 24 hours. When the reaction is substantially complete, the product is isolated by conventional means. EXAMPLES

[0396] The examples below depict the general synthetic procedure for the compounds described herein. Synthesis of the compounds described herein is not limited by these examples and schemes. One skilled in the art will know that other procedures can be used to synthesize the compounds described herein, and that the procedures described in the examples and schemes is only one such procedure. In the descriptions below, one of ordinary skill in the art would recognize that specific reaction conditions, added reagents, solvents, and reaction temperatures can be modified for the synthesis of specific compounds that fall within the scope of this disclosure. Unless otherwise specified, intermediate compounds in the examples below, that do not contain a description of how they are made, are either commercially available to one skilled in the art, or can otherwise be synthesized by the skilled artisan using commercially available precursor molecules and synthetic methods known in the art.

[0397] The following Schemes and synthetic examples are intended to be illustrative and are not limiting or restrictive to the scope of the disclosure. Example 1 [Image disponible dans le document PDF, Image available in the PDF document]

[0398] Step 1: Preparation of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1-(phenylsulfonyl)-1H- pyrrolo[2,3-b]pyridin-3-yl)picolinate 2: To a microwave pressure vial charged with 4-[1- (benzenesulfonyl)-3-iodo-pyrrolo[2,3-b]pyridin-5-yl]-3,5-dimethyl-isoxazole (1, 150 mg, 0.313 mmol), methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate (167 mg, 0.635 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (26.6 mg, 0.033 mmol) was added 1,4-dioxane (3 ml). The flask was flushed with argon and then 2.5M aqueous potassium carbonate (0.376 ml) was added. The vial was sealed and allowed to stir in an oil bath at 120 °C for 2 hours. The reaction was allowed to cool to room temperature and the biphasic mixture was filtered through Celite washing with THF and ethyl acetate. The filtrate was concentrated under reduced pressure and the material was purified by silica gel flash column chromatography eluting with a gradient from 0 - 100% ethyl acetate in hexane. This provided methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1- (phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)picolinate (2). MS (ESI) <semantics>[M+H†]†=489.0<annotation encoding="application / x-tex">[M+H^{\dagger}]^{\dagger} = 489.0< / annotation>< / semantics>.

[0399] Step 2: Preparation of 4-(5-(3,5-dimethylisoxazol-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3- b|pyridin-3-yl)picolinic acid P-0055: A solution of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1- (phen / sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)picolinate (2, 78.5 mg, 0.16 mmol) dissolved in dioxane (6 ml) was cooled in an ice bath. Then, 3 ml of 1M LiOH (aqueous) was added. After 30 min, the reaction was quenched with 1 M HCl (aqueous) to a pH of 1 and then extracted with ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and filtered. The volatiles were removed by rotary evaporation and the resulting residue was purified by reverse phase HPLC (C18; 0- 100% B; A: 5% CH3CN, 95% H2O, 0.1% HCO2H; B: 95% CH3CN, 5% H2O, 0.1% HCO2H) to provide 4-(5-(3,5-dimethylisoxazol-4-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)picolinic acid (P- 0055). MS (ESI) <semantics>[M+H+]+=474.9<annotation encoding="application / x-tex">[M+H^+]^+ = 474.9< / annotation>< / semantics>. Example 2 [Image disponible dans le document PDF, Image available in the PDF document]

[0400] Step 1: Preparation of 4-(3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3,5- dimethylisoxazole 4: In a round flask charged with 4-(3-iodo-1H-pyrrolo[2,3-b]pyridin-5-yl)-3,5- dimethyl-isoxazole (3, 10 g, 29.5 mmol) and anhydrous THF (150 ml) was added sodium hydride (60%, 1.65 g, 41.3 mmol). The reaction was allowed to stir at room temperature for 1 hour followed by the addition of 4-methylbenzenesulfonyl chloride (6.80 g, 35.7 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with brine (160 mL) and diluted with ethyl acetate (160 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was dry-loaded onto silica gel and purified by silica gel flash column chromatography eluting with 0-20% ethyl acetate in hexane to give 4-(3-iodo-1- tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3,5-dimethylisoxazole (4). MS (ESI) <semantics>[M+H+]+<annotation encoding="application / x-tex">[M+H^+]^+< / annotation>< / semantics> = 493.9.

[0401] Step 2: Preparation of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1-tosyl-1H-pyrrolo[2,3- b|pyridin-3-yl)-2,2-dimethylbut-3-ynoate 5: A mixture of 4-(3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridin- 5-yl)-3,5-dimethylisoxazole (4, 104 mg, 0.21 mmol), bis(triphenylphosphine) palladium(II) dichloride (4.42 mg, 6.3 umol) and copper(I) iodide (1.2 mg, 6.3 umol) in (1:3) triethylamine in acetonitrile (2.0 ml) was purged with nitrogen gas, then methyl 2,2-dimethylbut-3-ynoate (53 mg, 0.42 mmol) was added. The mixture was heated at 90 °C for 2 hours. The mixture was concentrated down under reduced pressure and purified by flash chromatography eluting with 20% ethyl acetate in hexane to provide methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3- ynoate (5). MS (ESI) <semantics>[M+H+]+=492.2<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 492.2< / annotation>< / semantics>.

[0402] Step 3: Preparation of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin- 3-yl)-2,2-dimethylbut-3-ynoate 6: To a mixture of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1-tosyl-1H- pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3-ynoate (5, 88 mg, 0.18 mmol) in THF (2 ml) was added 1M TBAF in THF (0.400 ml). The mixture was allowed to stir at 70 °C for 15 hours. The reaction was diluted with ethyl acetate which was washed with saturated sodium bicarbonate (aqueous), water and then brine. The layers were separated and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure and was triturated with 5% ethyl acetate in hexane to provide methyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3- ynoate (6). MS (ESI) <semantics>[M+H+]+=338.6<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 338.6< / annotation>< / semantics>.

[0403] Step 4: Preparation of methyl 4-(1-benzyl-5-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[2,3- b|pyridin-3-yl)-2,2-dimethylbut-3-ynoate 7: To a mixture of methyl 4-(5-(3,5-dimethylisoxazol-4-yl)- 1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3-ynoate (6, 28.6 mg) in DMF (1 ml) was added 60% NaH in mineral oil (60%, 4.07 mg, 0.1 mmol). The mixture was allowed to stir for 2 minutes and then bromomethylbenzene (21.75 mg, 0.13 mmol) was added. The resulting mixture was stirred at 60 °C for 2 hours. The mixture was diluted with water, extracted with ethyl acetate and the organic layer was washed with water, followed by brine. The layers were separated and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The material was purified by flash chromatography eluting with 50% ethyl acetate in hexane to provide methyl 4-(1-benzyl-5-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3-ynoate (7). MS (ESI) [M+H+]+ <semantics>=428.6.<annotation encoding="application / x-tex">=428.6.< / annotation>< / semantics>

[0404] Step 5: Preparation of 4-(1-benzyl-5-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[2,3- b|pyridin-3-yl)-2,2-dimethylbut-3-ynoic acid P-0051: To a mixture of methyl 4-(1-benzyl-5-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3-ynoate (7, 22.6 mg, 0.05 mmol) in (1:1) THF / MeOH (0.5 ml) was added 4.18 M LiOH (0.030 ml). The mixture was stirred at 70 °C for 3 hours. The reaction was acidified with 3N HCl in MeOH and concentrated under reduced pressure. The material was purified by reverse phase HPLC (C18; 0-100% B; A: 5% CH3CN, 95% H2O, 0.1% HCO2H; B: 95% CH3CN, 5% H2O, 0.1% HCO2H) to provide 4-(1-benzyl-5-(3,5-dimethylisoxazol- 4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2-dimethylbut-3-ynoic acid (P-0051). MS (ESI) <semantics>[M+H+]+=414.5<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 414.5< / annotation>< / semantics>. Example 3 [Image disponible dans le document PDF, Image available in the PDF document] Step 2 10 P-0160

[0405] Step 1: Preparation of (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[3,2-b]pyridin-6- yl)-3,5-dimethylisoxazole 9: To 4-(3-iodo-1H-pyrrolo[3,2-b]pyridin-6-yl)-3,5-dimethylisoxazole (8, 0.92 g, 2.71 mmol) in THF (20 ml) was added (1R)-1-(2-pyridyl)ethanol (0.38 g, 3.09 mmol) followed by triphenylphosphine (0.957 g, 3.65 mmol). The reaction was cooled to 0 °C in an ice water bath, followed by the dropwise addition of diisopropyl azodicarboxylate (0.738 g, 3.65 mmol). After 1 hour, the reaction was removed from the ice bath and allowed to warm to room temperature for 1 hour. The reaction was concentrated under reduced pressure and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-1H- pyrrolo[3,2-b]pyridin-6-yl)-3,5-dimethylisoxazole (9).

[0406] Step 2: Preparation of (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-2-(trifluoromethyl)-1H- pyrrolo[3,2-b]pyridin-6-yl)-3,5-dimethylisoxazole 10: To (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-1H- pyrrolo[3,2-b]pyridin-6-yl)-3,5-dimethylisoxazole (9, 0.91 g, 2.05 mmol) and zinc trifluoromethanesulfinate (1.36 g, 4.10 mmol) was added DMSO (10 ml) followed by water (4 ml). The reaction was cooled in an ice bath and tert-Butyl hydroperoxide (0.86 ml, 6.8 mmol) was added dropwise. The reaction was removed from the ice bath and allowed to warm to ambient temperature and then placed in an oil bath at 50 °C and allowed to stir overnight. After 22 hours, LCMS indicated ~10% product formation. An additional 1.27 g of zinc trifluoromethanesulfinate was added, followed by 1 ml of tert-Butyl hydroperoxide. The reaction was allowed to continue for an additional 17 hours at 50 °C. The reaction was extracted with saturated sodium bicarbonate and ethyl acetate. The organic layer was separated and the aqueous layer was extracted 3 more times with 5 mL portions of ethyl acetate. The organic layers were combined and volatiles removed by rotary evaporation to provide the crude product that was purified by silica gel column chromatography (10-60% ethyl acetate in hexanes). This provided (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-6-yl)-3,5- dimethylisoxazole (10). MS (ESI) <semantics>[M+H+]+=512.1<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 512.1< / annotation>< / semantics>.

[0407] Step 3: Preparation of (S)-3,5-dimethyl-4-(3-(1-methyl-1H-pyrazol-4-yl)-1-(1-(pyridin-2- yl)ethyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-6-yl)isoxazole P-160: To a reaction vial charged with (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-6-yl)- 3,5-dimethylisoxazole (10, 61.47 mg, 0.12 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)pyrazole (49.94 mg, 0.24 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (9.8 mg, 0.012 mmol) in dioxane (2 ml) and purged with nitrogen gas, was added 2.5M aqueous K2CO3 (0.144 ml) .The mixture was heated at 110 °C for 15 hours. The sample was diluted with ethyl acetate which was dried over anhydrous magnesium sulfate; filtered, concentrated down and purified by flash chromatography eluting with 100% ethyl acetate, followed by reversed chromatography to provide (S)-3,5-dimethyl-4-(3-(1-methyl-1H-pyrazol-4-yl)-1-(1-(pyridin-2-yl)ethyl)- 2-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-6-yl)isoxazole (P-0160). MS (ESI) <semantics>[M+H+]+=467.6<annotation encoding="application / x-tex">[M+H^+]^+ = 467.6< / annotation>< / semantics> Example 4 [Image disponible dans le document PDF, Image available in the PDF document]

[0408] Step 1 : Preparation of (3-(benzyloxy)phenyl)(6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)methanol 12: To 3,5-dimethyl-4-(1H-pyrrolo[3,2-b]pyridin-6-yl)isoxazole (11, 0.24 g, 1.11 mmol) in methanol (5ml) was added by potassium hydroxide (0.177 g, 3.15 mmol) and 3-benzyloxybenzaldehyde (0.26 g, 1.23 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was extracted with ethyl acetate and water with 1N citric acid. The organic layer was washed with water and brine, then dried over magnesium sulfate and filtered. The volatiles were removed under reduced pressure and the material was purified by silica gel column chromatography (0- 60% ethyl acetate in hexanes). This provided (3-(benzyloxy) phenyl)(6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)methanol (12). MS (ESI) <semantics>[M+H+]+=426.5<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 426.5< / annotation>< / semantics>.

[0409] Step 2: Preparation of (3-(benzyloxy)phenyl)(6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)methanone 13: To provided (3-(benzyloxy) phenyl)(6-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-3-yl)methanol (12, 34 mg, 0.080 mmol) in tetrahydrofuran (10 ml) was added by Dess-Martin periodinane (0.07 g, 0.16 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine, then dried over magnesium sulfate and filtered. The volatiles were removed under reduced pressure and the material was purified by silica gel column chromatography (0-100% ethyl acetate in dichloromethane) to provide (3- (benzyloxy)phenyl)(6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-3-yl)methanone (13). MS (ESI) <semantics>[M+H+]+=424.1.<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 424.1.< / annotation>< / semantics>

[0410] Step 3: Preparation of 4-(3-(3-(benzyloxy)benzoyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-1-yl)-3,5-dichlorobenzoic acid P-0133: To a mixture of (3- (benzyloxy)phenyl)(6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-3-yl)methanone (13, 29 mg, 0.068 mmol), 3,5-dichloro-4-fluoro-benzoic acid (40 mg, 0.19 mmol), and cesium carbonate (120 mg, 0.37 mmol) was added DMSO (3 ml). The reaction mixture was heated at 90 °C for 3 days. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine, then dried over magnesium sulfate and filtered. The volatiles were removed under reduced pressure and the crude material was purified by reverse phase HPLC (C18; 0-100% B; A: 5% CH3CN, 95% H2O, 0.1% HCO2H; B: 95% CH3CN, 5% H2O, 0.1% HCO2H) to provide 4-(3-(3- (benzyloxy)benzoyl)-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-dichlorobenzoic acid (<semantics>P<annotation encoding="application / x-tex">P< / annotation>< / semantics>-0133). MS (ESI) <semantics>[M+H+]+=612.0<annotation encoding="application / x-tex">[M+H^+]^+ = 612.0< / annotation>< / semantics>. Example 5 [Image disponible dans le document PDF, Image available in the PDF document]

[0411] Step 1: Preparation of ethyl 4-(6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1- yl)-3,5-diethoxybenzoate 14: 3,5-dimethyl-4-(1H-pyrrolo[3,2-b]pyridin-6-yl)isoxazole (11, 0.60 g, 2.81 mmol), ethyl 4-bromo-3,5-diethoxybenzoate (1.34 g, 4.21 mmol), potassium phosphate tribasic (1.25 g, 5.91 r mol), copper (I) iodide (0.11 g, 0.56 mmol), trans N,N'-dimethylcyclohexane-1,2-diamine (0.80 g, 5.6 mmol) were combined in toluene (6 ml) and flushed with argon. Then the reaction mixture was allowed to stir at 110 °C overnight. The reaction mixture was cooled to ambient temperature, diluted with 2 mL of ethyl acetate and filtered through a pad of Celite with ethyl acetate. This material was purified by silica gel column chromatography (0-50% ethyl acetate in hexane) to provide ethyl 4-(6-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoate (14).

[0412] Step 2: Preparation of ethyl 4-(3-bromo-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2- b|pyridin-1-yl)-3,5-diethoxybenzoate 15: To a 100 mL round bottom flask was added ethyl 4-(6-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoate (14, 620 mg, 1.38 mmol) and acetonitrile (14 mL). The reaction flask was placed under N2 and cooled to 0 °C, followed by the slow addition of N-bromosuccinimide (246 mg, 1.38 mmol). The reaction mixture was stirred at 0 °C and allowed to warm to room temperature for 2 hours. The reaction was diluted with ethyl acetate and partitioned between water and ethyl acetate. The extracted organic fraction was washed with brine and dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and was purified by silica gel column chromatography (0-60% ethyl acetate in hexane) to provide ethyl 4-(3- bromo-6-(3,5-dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoate (15).

[0413] Step 3: Preparation of 4-(3-(4-(cyclopropylcarbamoyl)phenyl)-6-(3,5-dimethylisoxazol-4- yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoic acid P-0218: Ethyl 4-(3-bromo-6-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoate (15, 40 mg, 0.08 mmol), (4- (cyclopropylcarbamoyl)phenyl)boronic acid (31 mg, 0.15 mmol), 1,1'-bis(diphenylphosphino)ferrocene- palladium(II) dichloride dichloromethane complex (8.7 mg, 0.011 mmol), and 2.5M aqueous K2CO3 (0.09 ml) were combined in dioxane / acetonitrile (0.5 ml each) and heated to 100 °C for 8hrs. The reaction was then cooled, filtered through celite, and purified by silica gel column chromatography (0- 10% methanol in dichloromethane) to provide 4-(3-(4-(cyclopropylcarbamoyl)phenyl)-6-(3,5- dimethylisoxazol-4-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-3,5-diethoxybenzoic acid (P-0218). MS (ESI) <semantics>[M+H+]+=581.2.<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 581.2.< / annotation>< / semantics> Example 6 [Image disponible dans le document PDF, Image available in the PDF document]

[0414] Step 1: Preparation of (S)-5-bromo-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine 17: To an ice cold solution of 5-bromo-1H-pyrrolo[2,3-b]pyridine (16, 689 mg, 3.5 mmol), (1R)-1-(2- pyridyl)ethanol (646 mg, 5.25 mmol) and triphenylphosphine (1377 mg, 5.25 mmol) in THF (35 ml) under nitrogen gas was added slowly diisopropylazodicarboxylate (1.04 ml, 5.25 mmol). The mixture was stirred and allowed to reach room temperature for 15 hours. The mixture was concentrated down under reduced pressure and was purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to provide (S)-5-bromo-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine (17). MS (ESI) <semantics>[M+H+]+=303.9<annotation encoding="application / x-tex">[M+H^+]^+ = 303.9< / annotation>< / semantics>.

[0415] Step 2: Preparation of (S)-3,5-dimethyl-4-(1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3- b]pyridin-5-yl)isoxazole 18: A mixture of (S)-5-bromo-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3- b]pyridine (17, 618 mg, 2.05 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)isoxazole (502 mg, 2.25 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (149 mg, 0.182 mmol) in dioxane (20 ml) was purged with nitrogen gas, then 2.5M K2CO3 (2.5ml) was added. The mixture was heated at 100 °C for 4 hours. The sample was diluted with ethyl acetate and dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The material was purified by silica gel column chromatography eluting with 40% ethyl acetate in hexane to provide (S)-3,5-dimethyl-4-(1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3-b]pyridin-5- yl)isoxazole (18). MS (ESI) <semantics>[M+H+]+=319.5<annotation encoding="application / x-tex">[M+H^{+}]^{+} = 319.5< / annotation>< / semantics>.

[0416] Step 3: Preparation of (S)-4-(3-iodo-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[2,3-b]pyridin-5- yl)-3,5-dimethylisoxazole 19: To an ice cold solution of (S)-3,5-dimethyl-4-(1-(1-(pyridin-2-yl)ethyl)- 1H-pyrrolo[2,3-b]pyridin-5-yl)isoxazole (18, 620 mg, 1.56 mmol) in acetonitrile (20 ml) was added N- iodosuccinimide (420 mg, 1.87 mmol). The mixtur...

Claims

<pat:Claims com:id="claims"> <pat:Claim com:id="CLM-00001"> <pat:ClaimNumber>1< / pat:ClaimNumber> <pat:ClaimText>1. A compound having Formulae IV(a) or IV(c): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: <semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics> is: [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein G1 is benzyloxy, -C(=CH2)CH3, -C(O)OH, -C(O)NH2, -C(O)N(H)-cyclopropyl, cyclopropyl, -CH2-cyclopropyl, cyclopropylalkynylene, -CH2-SO2-CH3, -SO2-CH3, -(CH2)N(CH3)2, -(CH2)2-N(CH3)2, -CH2-cyclopropyl, -(CH2)2-CN, -C(O)OC(CH3)3, -C(O)CH3, -C(O)C(CH3)3, <semantics>−CH2C(O)N(CH3)2<annotation encoding="application / x-tex">-CH_2C(O)N(CH_3)_2< / annotation>< / semantics>, CN, or <semantics>−SO2CH3<annotation encoding="application / x-tex">-SO_2CH_3< / annotation>< / semantics>; and each G2 is independently -OCHF2, -OCH2F, Cl, F, -OCH3, OH, -OCF3, CH3, -CH(CH3)2, CF3, CN, <semantics>−CH2CN<annotation encoding="application / x-tex">-CH_2CN< / annotation>< / semantics>, <semantics>CH2C(CH3)2(OH)<annotation encoding="application / x-tex">CH_2C(CH_3)_2(OH)< / annotation>< / semantics>, or <semantics>−C(CH3)2−OH<annotation encoding="application / x-tex">-C(CH_3)_2-OH< / annotation>< / semantics>. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00002"> <pat:ClaimNumber>2< / pat:ClaimNumber> <pat:ClaimText>2. The compound of claim <semantics>1<annotation encoding="application / x-tex">1< / annotation>< / semantics>, wherein -L-R1 is: [Image disponible dans le document PDF, Image available in the PDF document] < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00003"> <pat:ClaimNumber>3< / pat:ClaimNumber> <pat:ClaimText>3. A compound which is [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] ال P-0419 νN. О Ν HO O -, or [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00004"> <pat:ClaimNumber>4< / pat:ClaimNumber> <pat:ClaimText>4. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] • or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00005"> <pat:ClaimNumber>5< / pat:ClaimNumber> <pat:ClaimText>5. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00006"> <pat:ClaimNumber>6< / pat:ClaimNumber> <pat:ClaimText>6. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] . . or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00007"> <pat:ClaimNumber>7< / pat:ClaimNumber> <pat:ClaimText>7. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00008"> <pat:ClaimNumber>8< / pat:ClaimNumber> <pat:ClaimText>8. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00009"> <pat:ClaimNumber>9< / pat:ClaimNumber> <pat:ClaimText>9. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00010"> <pat:ClaimNumber>10< / pat:ClaimNumber> <pat:ClaimText>10. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] - - ' or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00011"> <pat:ClaimNumber>11< / pat:ClaimNumber> <pat:ClaimText>11. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] - - or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00012"> <pat:ClaimNumber>12< / pat:ClaimNumber> <pat:ClaimText>12. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] . or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00013"> <pat:ClaimNumber>13< / pat:ClaimNumber> <pat:ClaimText>13. The compound of claim 3, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] . or a pharmaceutically acceptable salt thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00014"> <pat:ClaimNumber>14< / pat:ClaimNumber> <pat:ClaimText>14. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 13, and a pharmaceutically acceptable carrier. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00015"> <pat:ClaimNumber>15< / pat:ClaimNumber> <pat:ClaimText>15. The pharmaceutical composition of claim 14, further comprising a second pharmaceutical agent. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00016"> <pat:ClaimNumber>16< / pat:ClaimNumber> <pat:ClaimText>16. Use of a compound as defined in any one of claims 1-13, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, or a pharmaceutical composition as defined in any one of claims 14-15, for treating a subject with a disease or condition mediated by EP300 or CBP. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00017"> <pat:ClaimNumber>17< / pat:ClaimNumber> <pat:ClaimText>17. Use of a compound as defined in any one of claims 1-13, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, or a pharmaceutical composition as defined in any one of claims 14-15, in the manufacture of a medicament for treating a subject with a disease or condition mediated by EP300 or CBP. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00018"> <pat:ClaimNumber>18< / pat:ClaimNumber> <pat:ClaimText>18. The use according to claim 16 or 17, wherein the disease or condition is a cancer that harbors inactivating mutations in CBP or EP300, or a cancer where there is activation of EP300 or CBP. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00019"> <pat:ClaimNumber>19< / pat:ClaimNumber> <pat:ClaimText>19. The use according to claim 16 or 17, wherein the disease or condition is a cancer that expresses an androgen receptor. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00020"> <pat:ClaimNumber>20< / pat:ClaimNumber> <pat:ClaimText>20. The use according to claim 16 or 17, wherein the disease or condition is a neoplastic disorder, an age-related disease, an inflammatory disorder, a cognitive disorder or a neurodegenerative disease. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00021"> <pat:ClaimNumber>21< / pat:ClaimNumber> <pat:ClaimText>21. The use of claim 20, wherein the neoplastic disorder is cancer. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00022"> <pat:ClaimNumber>22< / pat:ClaimNumber> <pat:ClaimText>22. The use according to claim 16 or 17, wherein the disease or condition is bladder cancer, adenocarcinoma, bone cancer, colorectal cancer, glioblastoma multiforme, glioma, gastric cancer, leukemia, lymphoma, small cell lung cancer, non-small cell lung cancer, malignant peripheral nerve sheath tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, breast cancer, medulloblastoma, melanoma, merkel cell cancer, mesothelioma, multiple myeloma, neuroblastoma, neurofibroma, osteosarcoma, ovarian cancer, prostate cancer, pancreatic cancer, skin cancer, Alzheimer's disease, Parkinson's disease, or colorectal cancer. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00023"> <pat:ClaimNumber>23< / pat:ClaimNumber> <pat:ClaimText>23. The use of claim 22, wherein the leukemia is acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia / lymphoma, aggressive NK-cell leukemia, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, or mast cell leukemia. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00024"> <pat:ClaimNumber>24< / pat:ClaimNumber> <pat:ClaimText>24. The use of claim 22, wherein the melanoma is acral lentiginous melanoma, nodular melanoma, or uveal melanoma. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00025"> <pat:ClaimNumber>25< / pat:ClaimNumber> <pat:ClaimText>25. The use of claim 22, wherein the lymphoma is AIDS-related lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, enteropathy-associated T-cell lymphoma, follicular lymphoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, MALT lymphoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, or T-cell lymphoma. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00026"> <pat:ClaimNumber>26< / pat:ClaimNumber> <pat:ClaimText>26. The use of claim 22, wherein the disease or condition is small-cell lung cancer, non- small cell lung cancer, bladder cancer, non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, diffuse large B-cell lymphoma, breast cancer or prostate cancer. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00027"> <pat:ClaimNumber>27< / pat:ClaimNumber> <pat:ClaimText>27. The use of claim 22, wherein the disease or condition is Alzheimer's disease or Parkinson's disease. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00028"> <pat:ClaimNumber>28< / pat:ClaimNumber> <pat:ClaimText>28. The use of any one of claims 16-27, wherein the compound, pharmaceutically acceptable salt, deuterated analog, tautomer, stereoisomer or pharmaceutical composition is for administration in combination with one or more additional therapeutic agents. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00029"> <pat:ClaimNumber>29< / pat:ClaimNumber> <pat:ClaimText>29. The use of claim 28, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent; ii) an antibiotic; iii) an antimetabolite; iv) an immunotherapy agent; v) a hormone or hormone antagonist; vi) a taxane; vii) a retinoid; viii) an alkaloid; ix) an antiangiogenic agent; x) a topoisomerase inhibitor; xi) a kinase inhibitor; xii) a targeted signal transduction inhibitor; xiii) a biological response modifier; xiv) an IDO inhibitor; xv) a chemotherapeutic agent; xvi) a Mek inhibitor; xvii) a tyrosine kinase inhibitor; xviii) a c-Kit mutant inhibitor, xix) an EGFR inhibitor, xx) a PD-1 inhibitor, or xxi) an epigenetic modulator. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00030"> <pat:ClaimNumber>30< / pat:ClaimNumber> <pat:ClaimText>30. The use of claim 29, wherein the one or more additional therapeutic agents is an epigenetic modulator which is: (a) a DNA methyltransferase; (b) a histone or protein methyltransferase; (c) a histone demethylase; (d) a histone deacetylase inhibitor; (e) histone acetyltransferase; (f) other chromatin remodelers; or (g) a BET inhibitor. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00031"> <pat:ClaimNumber>31< / pat:ClaimNumber> <pat:ClaimText>31. The use of claim 30, wherein the epigenetic modulator is a histone deacetylase inhibitor which is: vorinostat, romidepsin, chidamide, panobinostat, belinostat, valproic acid, mocetinostat, abexinostat, entinostat, resminostat, givinostat, or quisinostat. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00032"> <pat:ClaimNumber>32< / pat:ClaimNumber> <pat:ClaimText>32. The use of claim 30, wherein the epigenetic modulator is a BRD4 inhibitor. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00033"> <pat:ClaimNumber>33< / pat:ClaimNumber> <pat:ClaimText>33. The use of claim 29, wherein the one or more additional therapeutic agents is a PD-1 inhibitor, quizartinib, enzalutamide, abiraterone, or a BRD4 inhibitor. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00034"> <pat:ClaimNumber>34< / pat:ClaimNumber> <pat:ClaimText>34. The use of claim 29, wherein the alkylating agent is adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, or treosulfan. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00035"> <pat:ClaimNumber>35< / pat:ClaimNumber> <pat:ClaimText>35. The use of claim 29, wherein the antibiotic is bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, or plicamycin. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00036"> <pat:ClaimNumber>36< / pat:ClaimNumber> <pat:ClaimText>36. The use of claim 29, wherein the antimetabolite is azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, or trimetrexate. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00037"> <pat:ClaimNumber>37< / pat:ClaimNumber> <pat:ClaimText>37. The use of claim 29, wherein the immunotherapy agent is a PD-1 or PD-L1 inhibitor. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00038"> <pat:ClaimNumber>38< / pat:ClaimNumber> <pat:ClaimText>38. The use of claim 29, wherein the hormone or hormone antagonist is enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, or toremifene. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00039"> <pat:ClaimNumber>39< / pat:ClaimNumber> <pat:ClaimText>39. The use of claim 29, wherein the taxane is DJ-927, docetaxel, TPI 287, paclitaxel or DHA-paclitaxel. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00040"> <pat:ClaimNumber>40< / pat:ClaimNumber> <pat:ClaimText>40. The use of claim 29, wherein the retinoid is alitretinoin, bexarotene, fenretinide, isotretinoin, or tretinoin. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00041"> <pat:ClaimNumber>41< / pat:ClaimNumber> <pat:ClaimText>41. The use of claim 29, wherein the alkaloid is etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, or vinorelbine. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00042"> <pat:ClaimNumber>42< / pat:ClaimNumber> <pat:ClaimText>42. The use of claim 29, wherein the antiangiogenic agent is AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, or thalidomide. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00043"> <pat:ClaimNumber>43< / pat:ClaimNumber> <pat:ClaimText>43. The use of claim 29, wherein the topoisomerase inhibitor is amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, or 9- aminocamptothecin. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00044"> <pat:ClaimNumber>44< / pat:ClaimNumber> <pat:ClaimText>44. The use of claim 29, wherein the kinase inhibitor is erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), vemurafenib, dabrafenib, trametinib, cobimetinib selumetinib or vatalanib. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00045"> <pat:ClaimNumber>45< / pat:ClaimNumber> <pat:ClaimText>45. The use of claim 29, wherein the targeted signal transduction inhibitor is bortezomib, geldanamycin, or rapamycin. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00046"> <pat:ClaimNumber>46< / pat:ClaimNumber> <pat:ClaimText>46. The use of claim 29, wherein the biological response modifier is imiquimed, interferon-<semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics> or interleukin-2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00047"> <pat:ClaimNumber>47< / pat:ClaimNumber> <pat:ClaimText>47. The use of claim 29, wherein the chemotherapeutic agent is 3-AP (3-amino-2- carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389), ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, a mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor; or an aromatase inhibitor. < / pat:ClaimText> < / pat:Claim> < / pat:Claims>